بر اساس عنوان

1
2
2
2 - Surgical and medical consultation in a psychiatric general hospital ward
3
2 × 2 Codes and Vertex Operator Algebras
4
2 × 250 GeV gamma-gamma collider at TESLA
5
2- Absorbing Sub Semi Modules of Partial Semi Modules
6
2- and 3-furancarboxylic acids: a comparative study using calorimetry, IR spectroscopy and X-ray crystallography
7
2- and 4-[18F]Fluorophenols from Baeyer-Villiger Oxidation of [18F]Fluorophenylketones and [18F]Fluorobenzaldehydes
8
2 Anti-cytokine therapy in rheumatoid arthritis
9
2 billion year old natural analogs for nuclear waste disposal: the natural nuclear fission reactors in Gabon (Africa)
10
2 dimensional cyclic representation of Uqsl2 and the 8-vertex Ising model
11
2 Dimensional finite stochastic breakup model of biomass particle breakup
12
2 Distal rectus femoris transfer in CP gait as a simultaneous and as a secondary procedure - is there a difference of its effects?
13
2 Fast Parallel Prime Number Sieves
14
2 Gbit/s 0.5 (mu)m complementary metal-oxide semiconductor optical transceiver with event-driven dynamic power-on capability
15
2 GHz 1H NMR in pulsed magnets
16
2 GHz controllable power amplifier in standard CMOS process for short-range wireless applications
17
2 Hafta-18 Aylık Bebeği Olan Annelerde Postpartum Depresyon Sıklığı ve Yaşam Kalitesi
18
2 Isotope imaging
19
2 KEV FILTERS OF QUASI-MONOCHROMATIC EPITHERMAL NEUTRONS
20
2 Markers for diagnosis
21
2 million expansion for Stuart Oil
22
2 million expansion for Stuart Oil
23
2 MV injector as the Elise front-end and as an experimental facility
24
2 School of Electrical, Mechanical and Mechatronic Systems, University of Technology Sydney, Ultimo, NSW 2007, Australia
25
2 The mechanism of creation of SLAP lesions in a dynamic shoulder model: The role of inferior subluxation
26
2 The oxidation hypothesis of atherosclerosis
27
2 The problem in shoulder joints for student sumo wrestlers
28
2 to 23 GHz BiFET low noise amplifier design flow and implementations in 0.25 μm SiGe BiCMOS technology
29
2 Unique CYP1 Genes Are Expressed in Response to 3-Methylcholanthrene Treatment in Rainbow Trout
30
2 W power source based on air–hydrogen polymer electrolyte membrane fuel cells and water–aluminum hydrogen micro-generator
31
2 W Yb-doped double-clad fiber superfluorescent source with 42 nm 3 dB bandwidth
32
2 Years follow up Sex Reassignment Surgery: Mental Health and its Associated Factors
33
2 μm mid-infrared optical spectra of Tm3+-doped germanium gallate glasses
34
2 m heat pipe-cryogenic targets for COSY-TOF experiment
35
2 m heat pipe-cryogenic targets for COSY-TOF experiment
36
2 T superconducting detector solenoid for the PANDA target spectrometer
37
2 T superconducting detector solenoid for the PANDA target spectrometer
38
2 μm fluorescence radiative dynamics and energy transfer between Er3+ and Tm3+ ions in silicate glass
39
2 μm spectroscopic investigation of Tm3+-doped tellurite glass fiber
40
2 μm thin film c-Si cells on near-Lambertian Al2O3 substrates
41
2-((1H-Azol-1-yl)methyl)-N-arylbenzamides: Novel dual inhibitors of VEGFR-1/2 kinases
42
2-((2-((dimethylamino)methyl)phenyl)thio)-5-iodophenylamine (ADAM): an improved serotonin transporter ligand
43
2-(1-(Arylimino)ethyl)-8-arylimino-5,6,7-trihydroquinolylcobalt dichloride: Synthesis and polyethylene wax formation Original Research Article
44
2-(1-(Dimethylamino)ethyl)phenylpalladium(II) complexes 5-functionalized with fluorous silyl tails
45
2-(1,2,3-Triazol-4-yl)pyridine-containing ethynylarenes as selective ‘turn-on’ fluorescent chemosensors for Ni(II)
46
2-(1-{2,6-Bis[bis(4-fluorophenyl)methyl]-4-methylphenylimino}ethyl)-6-[1-(arylimino)ethyl]pyridylcobalt dichlorides: Synthesis, characterization and ethylene polymerization behavior
47
2-(1′-Hydroxyethyl)-anthraquinone as a photolabile protecting group for carboxylic acids
48
2-(1-Arylimino)quinolylnickel halides: Synthesis, characterization and catalytic behavior towards ethylene
49
2-(1-Aryliminoethyl)cycloheptapyridylpalladium complexes: Synthesis, characterization and the use in the Heck-reaction
50
2-(1-Aryliminoethylidene)quinolylnickel(II) dibromides: Synthesis, characterization and ethylene dimerization capability
51
2(1H)-Quinolinone derivatives as novel anti-arteriostenotic agents showing anti-thrombotic and anti-hyperplastic activities
52
2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium Tetrafluoroborate as an Efficient Coupling Reagent for the Amidation and Phenylhydrazation of Carboxylic Acids at Room Temperature
53
2-(1H-Imidazol-4-yl)ethanamine and 2-(1H-pyrazol-1-yl)ethanamine side chain variants of the IGF-1R inhibitor BMS-536924
54
2-(1-Isopropyl-2-benzimidazolyl)-6-(1-aryliminoethyl)pyridyl transition metal (Fe, Co, and Ni) dichlorides: Syntheses, characterizations and their catalytic behaviors toward ethylene reactivity
55
2-(2-(2-Ethoxybenzoylamino)-4-chlorophenoxy)-N-(2-ethoxybenzoyl)benzamine inhibits EAT cell induced angiogenesis by down regulation of VEGF secretion
56
2-(2-(4-Benzoylpiperazin-1-yl)ethyl)isoindoline-1,3-dione derivatives: Synthesis, docking and acetylcholinesterase inhibitory evaluation as anti-alzheimer agents
57
2-(2,2,2-Trifluoroethyl)-5,6-dichlorobenzimidazole derivatives as potent androgen receptor antagonists
58
2-(2,4-Dimethoxybenzylidene)-N-Phenylhydrazinecarbothioamide as an Efficient Corrosion Inhibitor for Mild Steel in Acidic Environment
59
2-(2-{Diphenylarsino}ethyl)-1,3-dioxane (L1) and 2-(diphenylarsinomethyl)tetrahydrofuran (L2) and their palladium(II), platinum(II) and mercury(II) complexes: synthesis and crystal structures of [PdBr2(L1)2] and [HgBr2(L2)]2
60
2-(2′-Pyridyl)benzimidazole as a fluorescent probe for monitoring protein–surfactant interaction
61
2-(2-Chloro-6-fluorophenyl)acetamides as potent thrombin inhibitors
62
2-(2-Furanyl)-7-phenyl[1,2,4]triazolo[1,5-c]pyrimidin-5-amine analogs as adenosine A2A antagonists: The successful reduction of hERG activity. Part 2
63
2-(2-Furanyl)-7-phenyl[1,2,4]triazolo[1,5-c]pyrimidin-5-amine analogs: Highly potent, orally active, adenosine A2A antagonists. Part 1
64
2-(2-Hydroxy-3-alkoxyphenyl)-1H-benzimidazole-5-carboxamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors
65
2(2-hydroxyphenyl)2H-benzotriazole ultraviolet stabilizers
66
2-(2-Phenyl-1H-phenanthro-[9,10-d]imidazole-1-yl)-acetic acid (PPIA) and its application for determination of amines by high performance liquid chromatography with fluorescence detection and identification with mass spectroscopy/atmospheric pressure chemi
67
2-(2-Pyridyl)ethylsilyl Group as a New Class of Electroauxiliary. Fine Tuning of the Electron Transfer Driven Reactions by the Dynamic Coordination to Silicon
68
2-(2-Selenocyanic acid ethyl ester)-1H-benz[de] isoquinoline-1,3-(2H)-dione, synthesis photophysics and interaction with bovine serum albumin: A spectroscopic approach
69
2-(3,4-Dihydro-1H-isoquinolin-2yl)-pyridines as a novel class of NR1/2B subtype selective NMDA receptor antagonists
70
2-(3,5-Dimethylphenyl)tryptamine Derivatives that Bind to the GnRH Receptor
71
2-(3-Amino-3-deoxy-β-d-xylofuranosyl)thiazole-4-carboxamide: A new tiazofurin analogue with potent antitumour activity
72
2-(3-Aminopropyl)-4-pentenoic acid as a bio-compatible/cleavable linker for solid-phase organic synthesis
73
2-(3-Ferrocenylpyrazol-1-yl)cyclohexanol: a new building block for ferrocenyl ligands
74
2-(4,5-Dihydroimidazol-2-yl)benzimidazoles as highly selective imidazoline I2/adrenergic α2 receptor ligands Original Research Article
75
2-(4-Carboxyphenyl)-6-N,N-diethylaminobenzofuran: a useful reagent for the sensitive determination of alcohols by high-performance liquid chromatography with fluorimetric detection
76
2-(4-Ethoxyphenlytelluromethyl)tetrahydro-2H-pyran (L1) and 2-(2-{4-ethoxyphenyl}telluroethyl)-1,3-dioxane (L2): synthesis, reactions of L1 with iodine and ligation of L1 with Ru(II), Cu(I), and Hg(II) and L2 with Ru(II). Crystal structures of [RuCl2(p-cy
77
2-(4-Fluorophenyl)-N-phenylacetamide Derivatives as Anticancer Agents: Synthesis and In-vitro Cytotoxicity Evaluation
78
2-(4-Methoxyphenoxy)-5-nitro-N-(4-sulfamoylphenyl)benzamide activates Kir6.2/SUR1 KATP channels
79
2-(4-Sulfophenylsulfonyl)ethoxycarbonyl group: a new water-soluble N-protecting group and its application to solid phase peptide synthesis in water
80
2-(5-Hydrazinocarbonyl-2-thienyl) -5, 6-methylenedioxybenzofuran and 2-(5-hydrazinocarbonyl-2-furyl)-5, 6-methylenedioxybenzofuran as novel fluorescence derivatisation reagents for carboxylic acids in liquid chromatography
81
2-(Acyloxy)ethylphosphonate analogues of prenyl pyrophosphates: synthesis and biological characterization Original Research Article
82
2-(Alkylthio)pyrimidin-4-ones as novel, reversible inhibitors of lipoprotein-associated phospholipase A2
83
2-(Aminomethyl)-benzamide-based glycine transporter type-2 inhibitors
84
2-(Ammoniummethyl) pyridinium dihydrogen squarate hydrate: An experimental and theoretical study
85
2-(Anilino)imidazolines and 2-(benzyl)imidazoline derivatives as h5-HT1D serotonin receptor ligands
86
2-(Anilinomethyl)imidazolines as α1 adrenergic receptor agonists: α1a subtype selective 2′-heteroaryl compounds
87
2-(Anilinomethyl)imidazolines as α1A Adrenergic Receptor Agonists: 2′-Heteroaryl and 2′-Oxime Ether Series
88
2-(Anilinomethyl)imidazolines as α1-adrenoceptor agonists: the identification of α1A subtype selective 2′-carboxylic acid esters and amides
89
2-(Aryl)-3-furan-2-ylmethyl-thiazolidin-4-ones as selective HIV-RT Inhibitors Original Research Article
90
2-(Arylmethyl)-3-substituted quinuclidines as selective α7 nicotinic receptor ligands
91
2-(Aryloxymethyl) azacyclic analogues as novel nicotinic acetylcholine receptor (nAChR) ligands
92
2-(Arylsulfinylmethyl)oxazinanes: chiral carbonyl equivalents. Application to the asymmetric synthesis of 1,2,3,4-tetrahydro-β-carbolines
93
2-(Azidomethyl)benzoyl as a new protecting group in nucleosides
94
2-(Benzimidazol-2-yl)-1,10-phenanthrolyl metal (Fe and Co) complexes and their catalytic behaviors toward ethylene oligomerization
95
2-(Chlorocarbonyl)-2-mesitylketene, a new building block for the synthesis of 4-hydroxy-3-mesityl tetronic acids
96
2-(Dimethylaminomethyl)-tetrahydroisoxazolopyridobenzazepine derivatives. Synthesis of a new 5-HT2C antagonist with potential anxiolytic properties
97
2-(Dimethyloctylsilyl)ethyl lactoside: a versatile intermediate for chemical and enzymic ganglioside synthesis
98
2-(Dimethylphosphinomethyl)- and 2-(methylthiomethyl)phenyl silicon compounds: higher coordination with soft donors
99
2-(Ethoxycarbonylmethyl)-1H-naphtho[1,8-de]-1,2,3-triazine anion: a new glycine enolate equivalent
100
2-(Ethoxycarbonylmethyl)-1H-naphtho[1,8-de]-1,2,3-triazine anion: a new glycine enolate equivalent
101
2-(Ethoxycarbonylmethyl)-1H-naphtho[1,8-de]-1,2,3-triazine anion: a new glycine enolate equivalent
102
2-(Fluorophenyl)pyridines by the Suzuki–Miyaura method: Ag2O accelerates coupling over undesired ipso substitution (SNAr) of fluorine
103
2(H)-1,4-Oxazin-2-ones as ambident azadienes
104
2(n1+n2)-(k1+k2) Fractional factorial split-plot designs containing clear effects
105
2-(N-Acyl) and 2-N-acyl-N6-substituted analogues of adenosine and their affinity at the human adenosine receptors
106
2-(N-Allylaminomethyl)cinnamaldehydes as substrates for syntheses of aza-polycycles via intramolecular cycloaddition reactions
107
2-(N-Hydroxylamino) sulfone synthesis by indium–iodine-triggered aza-Michael type addition of nitroarenes to vinyl sulfones
108
2-(N-Methylanilino)-3-formylchromone—a versatile synthon for incorporation of chromone moiety in a variety of heterocyclic systems and macrocycles through reactions with bifunctional nucleophiles
109
2-(Phenylthio)ethyl as a Novel Two-Stage Base Protecting Group for Thymidine Analogues
110
2-(p-Nitrophenylthioureido)-3-aminonaphtho-1,4-quinone as a water tolerant F− anion probe
111
2-(Prenyloxymethyl)benzoyl (POMB) as a new temporary protecting group for alcohols
112
2-(Prenyloxymethyl)benzoyl (POMB) group: a new temporary protecting group removable by intramolecular cyclization
113
2-(R-1H-Benzoimidazol-2-yl)-6-(1-aryliminoethyl)pyridyliron(II) dichlorides: Synthesis, characterization and the ethylene oligomerization behavior
114
2(S)-(Cycloalk-1-enecarbonyl)-1-(4-phenyl-butanoyl)pyrrolidines and 2(S)-(aroyl)-1-(4-phenylbutanoyl)pyrrolidines as prolyl oligopeptidase inhibitors Original Research Article
115
2-(Trifluoromethyl)acrylic acid: a novel functional monomer in non-covalent molecular imprinting
116
2-(Trimethylsilyl)ethanesulfonyl amide as a new ammonia equivalent for palladium-catalyzed amination of aryl halides
117
2-(Trimethylsilyl)ethanol as a new alcohol equivalent for copper-catalyzed coupling of aryl iodides
118
2*40 Gbit/s RZ-DQPSK transmission with tunable chromatic dispersion compensation in 263 km fibre link
119
2, 2′-Dihydroxyazobenzene-based fluorescent system for the colorimetric ‘turn-on’ sensing of cyanide
120
2, 3-(2-alkylthio)-6,7-bis(2-alkylthio)TTF: a new and green synthetic anticorrosive inhibitors for mild steel in 1.0 HCl
121
2, 3-Dihydrazone cellulose: Prospective material for tissue engineering scaffolds
122
2, 4-D Dichlorophenoxyacetic Acid Poisoning; Case Report and Literature Review
123
2,000 sets of Airbus wings
124
2,1,3-Benzothiadiazole-containing donor–acceptor–acceptor dyes for dye-sensitized solar cells
125
2,1,3-Benzoxadiazole-based selective chromogenic chemosensor for rapid naked-eye detection of Hg2+ and Cu2+
126
2,15-Dihydroxy-hexahelicene (HELIXOL): synthesis and use as an enantioselective fluorescent sensor
127
2,2,2-Trifluoroethyl 6-thio-β-d-glucopyranoside as a selective tag for cysteines in proteins Original Research Article
128
2,2,2-Trifluoroethyl methacrylate-graft-natural rubber: Synthesis and application as compatibilizer in natural rubber/fluoroelastomer blends
129
2,2,3,3,11,11,12,12-Octamethyl-1,4,7,10,13-pentaoxacyclohexadecane: improved synthesis and crystal structure with NaSCN
130
2,2,3,3,6,6-Hexachlorobiphenyl Hydroxylation by Active Site Mutants of Cytochrome P450 2B1 and 2B11
131
2,2,4,4-Tetrathio substituted 1,3-dithietanes
132
2,2,6,6-Tetramethylcyclohexanethione S-methylide, a highly hindered thiocarbonyl ylide: two-step cycloadditions
133
2,2,6,6-Tetramethylpiperidine-1-yloxyl bound to the imidazolium ion by an acetamido group for investigation of ionic liquids
134
2,2ʹ:6ʹ,2ʹʹ-Terpyridine metal complexes as building blocks for extended functional metallo-supramolecular assemblies and polymers
135
2,2′-(Disulfanedi­yl)di­benzoic acid N,N-di­methyl­formamide monosolvate: crystal structure, Hirshfeld surface analysis and computational study
136
2,2′,3,3′,4,4′-Hexachlorobiphenyl subchronic toxicity in rats
137
2,2′,3,4-Tetrahydroxy-3′-sulpho-5′-nitroazobenzene for spectrophotometric determination of aluminium in pharmaceutical suspensions and granite Original Research Article
138
2,2′:6′,2″-Terpyridine and bis(2,2′:6′,2″-terpyridine)ruthenium(II) complex on the dendritic periphery
139
2,2′:6′,2″-Terpyridine complexes of molybdenum(II) and tungsten(II). X-ray crystal structures of [MoI(CO)(terpy)(η2-PhC2Ph)]I and [WI(terpy)(η2-PhC2Ph)2]I·CDCl3
140
2,2′:6′,2″-Terpyridine[hydroxypropyl-β-cyclodextrin] 1:3 complex used as chelating agent for the determination of iron with a sensitive, selective and fast liquid chromatographic method Original Research Article
141
2,2′-Azobis (4-Methoxy-2,4-Dimethylvaleronitrile), a New Lipid-Soluble Azo Initiator: Application to Oxidations of Lipids and Low-Density Lipoprotein in Solution and in Aqueous Dispersions
142
2,2′-Biphenyldiol-bridged bis(free base porphyrin): synthesis and chiroptical probing of asymmetric amino alcohols
143
2,2′-Bipyridine and related N-chelants as very effective promoters for Cu catalysts in the decarboxylation
144
2,2′-Bipyridine, 2-(2-oxazolyl)pyridine and 2,2′-bisoxazole derived nickel(0) complexes as selective catalysts for cross-coupling of aryl chlorides by intramolecularly stabilized dialkylaluminum reagents
145
2,2′-Bipyridine,1,10-phenanthroline and 2,2′:6′,2″-terpyridine in gallium(III) chemistry: Complexes containing the core
146
2,2′-Bipyridinebutyldithiocarbamatoplatinum(II) and palladium(II) complexes: Synthesis, characterization, cytotoxicity, and rich DNA-binding studies Original Research Article
147
2,2′-Bipyrimidine transition metal complexes: Synthesis, reaction chemistry and solid state structures
148
2,2′-Bis((di-tert-butylphosphino)methyl)-1,1′-biphenyl (ditbi): a bulky analogue of bisbi. The crystal structure of [Rh2Cl2(1,5-cod)2(μ-ditbi)]
149
2,2′-Bis(diarylstibano)-1,1′-binaphthyls (BINASbs); a useful chiral ligand for palladium-catalyzed asymmetric allylic alkylation, and the structure of a BINASbPdCl2 complex
150
2,2′-Diamino-6,6′-dimethylbiphenyl as an efficient ligand in the palladium-catalyzed Suzuki–Miyaura and Mizoroki–Heck reactions
151
2,2′-Diaminoazo-benzene, a potential scaffold for the synthesis of bis-ureas and thioureas: Solution phase anion sensing and binding studies
152
2,2′-Dilithiobiphenyl by direct lithiation of biphenylene
153
2,2′-dithiobisbenzamides derived from α-, β- and γ-amino acids possessing anti-HIV activities: synthesis and structure–activity relationship Original Research Article
154
2,2′-Oxydiacetato-bridged complexes containing Sm(III) and bivalent cations. Synthesis, structure, magnetic properties and chemical speciation
155
2,2′-Pyridoin derivatives protect HL-60 cells against oxidative stress
156
2,2-Bipyridine: An Efficient Ligand in the Cobalt-Catalyzed Synthesis of Organozinc Reagents from Aryl Chlorides and Sulfonates
157
2,2-Bipyrimidine- and 2,3-bis(2-pyridyl)pyrazine-containing manganese(II) compounds: structural and magnetic properties
158
2,2-Bis(3-allyl-4-hydroxyphenyl)hexafluoropropane and fluorosiloxane as coating materials for nerve agent sensors
159
2,2-Dichlorination of Aldehydes with the 2,6-Lutidine·HCl/Cl2/CH2Cl2 System: an Environmentally Benign Process Suitable for Scale Up
160
2,2-Dichlorobiphenyl Decreases Amplitude and Synchronization of Uterine Contractions Through MAPK1-Mediated Phosphorylation of GJA1 (Connexin43) and Inhibition of Myometrial Gap Junctions
161
2,2-dicyanovinyl as a nonaromatic aryl bioisostere: synthesis, binding experiments and SAR studies of highly selective dopamine D4 receptor ligands
162
2,2-Dihydroperfluoropentane (HFC 4310 mf) synthesis from HFP dimer
163
2,2-Dihydroxy-methylcyclosiloxanes and other 2,2-difunctional methylcyclosiloxanes
164
2,2-Dimethoxy-propane as electrolyte additive for lithium-ion batteries
165
2,2-Dimethyl cyclopentanones by acid catalyzed ring expansion of isopropenylcyclobutanols. A short synthesis of ((plus-minus))-(alpha)-cuparenone and ((plus-minus))-herbertene
166
2,2-Dimethyl-2-(o-nitrophenyl)acetyl (DMNA) as an assisted cleavage protecting group for amines
167
2,2-Dimethyl-2H-anthra[2,3-b]pyran-6,11-diones: a new class of cytotoxic compounds Original Research Article
168
2,2-Dimethyl-4,5-diaryl-3(2H)furanone derivatives as selective cyclo-oxygenase-2 inhibitors
169
2,2-Disubstituted analogues of the natural hormone 1α,25-dihydroxyvitamin D3: chemistry and biology Original Research Article
170
2,2-Hydroxyphenylbenzoxazole as a selective chelating agent for complexation with Tin and Zinc: a voltammetry study
171
2,3,4,5-Tetrahydro- and 2,3,4,5,11,11a-hexahydro-1H-[1,4]diazepino[1,7-a]indoles: new templates for 5-HT2C agonists
172
2,3,5,6,7,8-Hexasilabicyclo[2.2.2]octane-1-carboxylic acids and esters: preparation and structure
173
2,3,5,6-Tetra(pyrazin-2-yl)pyrazine: a novel bis-bidentate, bis-tridentate chelator
174
2,3,5-Substituted tetrahydrofurans as cancer chemopreventives. Part 1: Synthesis and anti-cancer activities of 5-hydroxymethyl-2,3-diaryl-tetrahydro-furan-3-ols Original Research Article
175
2,3,5-Trimethylphenol oxidation over Co-based solid catalysts Original Research Article
176
2,3,5-Triphenyltetrazolium chloride (TTC) as electron acceptor of culturable soil bacteria, fungi and actinomycetes
177
2,3,6,7-Naphthalenetetracarboxylic dianhydride revisited
178
2,3,6-/3,4,5-Trimethyl substituted diaryl carotenoid derivatives (Chlorobiaceae) in petroleums of the Belarussian Pripyat River Basin
179
2,3,6-Trideoxy sugar nucleotides: synthesis and stability
180
2,3,7,8-Substituted PCDDs and PCDFs in sea lion (Otaria flavescens) skin biopsies from two South-western Atlantic populations
181
2,3,7,8-TCDD equivalence and mutagenic activity associated with PM10 from three urban locations in New Zealand
182
2,3,7,8-Tetrachlorodibenzo-p-dioxin induces a proteomic pattern that defines cleft palate formation in mice
183
2,3,7,8-Tetrachlorodibenzo-p-dioxin induces CYP1B1 expression in human luteinized granulosa cells
184
2,3,7-Trisubstituted pyrazolo[1,5-d][1,2,4]triazines: Functionally selective GABAA α3-subtype agonists
185
2,3′-disubstituted-2-(2′-carboxycyclopropyl)glycines as potent and selective antagonists of metabotropic glutamate receptors
186
2,392 emergency department intubations: First report of the ongoing National Emergency Airway Registry study (NEAR 97)
187
2,3-Anhydrosugars in glycoside bond synthesis. Application to the preparation of C-2 functionalized α-d-arabinofuranosides
188
2,3-Anhydrosugars in glycoside bond synthesis: application to furanosyl azides and C-glycosides
189
2,3-Benzodiazepin-1,4-diones as peptidomimetic inhibitors of γ-secretase
190
2,3-Butanediol fermentation promotes growth of Serratia plymuthica at low pH but not survival of extreme acid challenge
191
2,3-Butanedione monoxime cardioplegia: advantages over hyperkalemia in blood-perfused isolated hearts
192
2,3-Dehydro-4α-hydroxylongilactone, a novel quassinoid and two known phenyl propanoids from Eurycoma longifolia Jack
193
2,3-Diamino acid modifying 3S-tetrahydroisoquinoline-3-carboxylic acids: Leading to a class of novel agents with highly unfolded conformation, selective in vitro anti-platelet aggregation and potent in vivo anti-thrombotic activity Original Research Artic
194
2,3-Diaminopyridine as a platform for designing structurally unique nonpeptide bradykinin B1 receptor antagonists
195
2,3-Diaryl-5-anilino[1,2,4]thiadiazoles as melanocortin MC4 receptor agonists and their effects on feeding behavior in rats Original Research Article
196
2,3-Diarylbenzopyran derivatives as a novel class of selective cyclooxygenase-2 inhibitors
197
2,3-Diarylpyran-4-ones: a new series of selective cyclooxygenase-2 inhibitors
198
2,3-Diarylthiophenes as selective EP1 receptor antagonists
199
2,3-Dichloro-5,6-dicyano-p-benzoquinone (DDQ) as a Highly Efficient and Mild Catalyst for Diethyl Acetalization of Carbonyl Compounds
200
2,3-Dihydro-1,3-dioxo-1H-isoindole-5-carboxylic acid derivatives: a novel class of small molecule heparanase inhibitors
201
2,3-Dihydro-1H-1,3-diazepin-2-ones: synthesis and novel rearrangements into pyrrole derivatives
202
2,3-Dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butylbenzofuran: Design and Evaluation as a Novel Radical-Scavenging Antioxidant against Lipid Peroxidation
203
2,3-Dihydro-6,7-dichloro-pyrido[2,3-b]pyrazine-8-oxide as selective glycine antagonist with in vivo activity Original Research Article
204
2,3-Dihydro-dithiin and -dithiepine-1,1,4,4-tetroxides: small molecule non-peptide antagonists of the human galanin hGAL-1 receptor Original Research Article
205
2,3-Dihydrofarnesyl and citronellyl esters in the paracloacal gland secretions of the brown caiman (Caiman crocodilus fuscus) from Costa Rica
206
2,3-Dihydroimidazo[1,2-b]ferroceno[d]pyridazines and a 3,4-dihydro-2H-pyrimido[1,2-b]ferroceno[d]pyridazine: Synthesis, structure and in vitro antiproliferation activity on selected human cancer cell lines
207
2,3-Dihydroisoindolones by cyclisation and rearomatisation of lithiated benzamides
208
2,3-Dihydroxypropyl methacrylate and 2-hydroxyethyl methacrylate hydrogels: gel structure and transport properties
209
2,3-Dimercaptopropanol, 2,3-dimercaptopropane-1-sulfonic acid, and meso-2,3-dimercaptosuccinic acid inhibit δ-aminolevulinate dehydratase from human erythrocytes in vitro
210
2,3-Dimethoxy-5-methyl-1,4-benzoquinones and 2-methyl-1,4-naphthoquinones: glycation inhibitors with lipid peroxidation activity
211
2,3-Dimethoxybenzo[i]phenanthridines: topoisomerase I-targeting anticancer agents Original Research Article
212
2,3-Dimethyl-2,3-diphenylbutane mediated grafting of vinyltriethoxysilane to polyethylene: a novel radical initiation system
213
2,3-Di-O-methoxymethyl-6-O-tert-butyldimethylsilyl-β-cyclodextrin, a useful stationary phase for gas chromatographic separation of enantiomers
214
2,3-Di-O-methoxymethyl-6-O-tert-butyldimethylsilyl-γ-cyclodextrin: a new class of cyclodextrin derivatives for gas chromatographic separation of enantiomers
215
2,3-Diphenylpropionic acids as potent VLA-4 antagonists
216
2,3-Diphenylquinoxaline-4′,4″-dioxytriethylene glycol as a sensing and selective material for construction of strontium-PVC membrane sensor
217
2,3-Disubstituted 6-azabicyclo[3.2.1]octanes as novel dopamine transporter inhibitors Original Research Article
218
2,3-Disubstituted pyrrolo[2,3-b]quinoxalines via aminopalladation–reductive elimination
219
2,3-Disubstituted quinuclidines as a novel class of dopamine transporter inhibitors Original Research Article
220
2,3-DPG-Hb complex: a hypothesis for an asymmetric binding Original Research Article
221
2,3-Epithiopropyl methacrylate as functionalized monomer in a dental adhesive
222
2,3-Ethylene- and 2,3-trimethylene-bridged analogues of the group III metabotropic glutamate receptor ligand 2-amino-4-phosphonobutanoic acid
223
2,3-Quinoxalinedione as a novel corrosion inhibitor for mild steel in 1 M HCl
224
2,3-Substituted 2-azanorbornanes as polar β-turn mimetics
225
2,3-Unsaturated enoses. A Pummerer rearrangement route to sugar vinyl sulfides and synthesis of 3-deoxy-3-alkyl/arylsulfinyl pyranosides
226
2,4- في استحداث الكالس وتحفيز الاجنه الخضريه من زراعه البراعم D و NAA تاثير الاوكسينان بتقنيه زراعه الانسجه Ananas comosus (L.) Merr. cv. DelMonte الابطيه لنبات الاناناس
227
2,4(5)-Diarylimidazoles: Synthesis and biological evaluation of a new class of sodium channel blockers against hNav1.2
228
2,4,4,5,7,7,8,8,9,9,9-Undecafluoro-2,5-bis(trifluoromethyl)-3,6-dioxanonyl methacrylate
229
2,4,5- triarylimidazole inhibitors of IL-1 biosynthesis
230
2,4,5-Trimethoxypropiophenone from Piper marginatum
231
2,4,5-Trisubstituted imidazoles: novel nontoxic modulators of P-glycoprotein mediated multidrug resistance. Part 1[]
232
2,4,5-Trisubstituted imidazoles: novel nontoxic modulators of P-glycoprotein mediated multidrug resistance. Part 2[]
233
2,4,5-Trisubstituted Thiazole Building Blocks by a Novel Multi-Component Reaction
234
2,4,6,8-Tetraiodoglycoluril in sulfuric acid as a new powerful reagent for iodination of deactivated arenes
235
2,4,6-tri(3,5-Dimethylpyrazoyl)-1,3,5-triazine modified carbon paste electrode for trace Cobalt(II) determination by differential pulse anodic stripping voltammetry
236
2,4,6-Trichloro-1,3,5-triazine catalyzed synthesis of thiiranes from oxiranes under solvent-free and mild conditions
237
2,4,6-Trihydroxyacetophenone on zeolite surface: Correlation between electronic relaxation and fragmentation on mass spectra
238
2,4,6-Trimethylpyridinium perchlorate: Polar properties and correlations with molecular structure of organic–inorganic hybrid crystal
239
2,4,6-Trinitrotoluene transformation by a tropical marine yeast, Yarrowia lipolytica NCIM 3589
240
2,4,6-Trinitrotoluene Transformation Using Spinacia Oleracea: Saturation Kinetics of the Nitrate Reductase Enzyme
241
2,4,6-Triphenylphenyltellurium(IV) triiodide – supramolecular self-assembling in organotellurium triiodides
242
2,4,6-Triphenylpyrylium ion encapsulated within Y zeolite as photocatalyst for the degradation of methyl parathion
243
2,4,6-Triphenylthiapyrylium cation as homogeneous solar photocatalyst
244
2,4,6-Tris(4-iodophenoxy)-1,3,5-triazine as a new recyclable “iodoarene” for in situ generation of hypervalent iodine(III) reagent for α-tosyloxylation of enolizable ketones
245
2,4,6-Trisubstituted pyridines: Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure–activity relationship Original Research Article
246
2,4,6-Trisubstituted pyrimidine derivatives as pregnancy interceptive agents Original Research Article
247
2,4,6-Tri-tert-butyl-1,3,5-triphosphabenzene as an (eta)6-Ligand in Transition Metal Complexes
248
2,4-Bis(fluorocarbon)-substituted phenols for high yield Newman–Kwart rearrangement reactions
249
2,4-Bis(methylsulfanyl)pyrimidine o-quinodimethane: a versatile building block for functionalized fused pyrimidines
250
2,4-Bis(octadecanoylamino)benzenesulfonic acid sodium salt as a novel scavenger receptor inhibitor with low molecular weight
251
2,4-Bridged 1,5-bis(fluoroalkyl)-1,3,5-triketones: synthesis and properties
252
2,4-D based herbicidal ionic liquids
253
2,4-D Exposure and risk assessment: Comparison of external dose and biomonitoring based approaches
254
2,4-Decadienal downregulates TNF-α gene expression in THP-1 human macrophages
255
2,4-Diamino-5-methyl-6-substituted arylthio-furo[2,3-d]pyrimidines as novel classical and nonclassical antifolates as potential dual thymidylate synthase and dihydrofolate reductase inhibitors Original Research Article
256
2,4-Diamino-9H-pyrimido[4,5-b]indol-5-ols: Synthesis, in vitro cytotoxic activity, and QSAR investigations Original Research Article
257
2,4-Diaminopyrimidines as histamine H4 receptor ligands—Scaffold optimization and pharmacological characterization Original Research Article
258
2,4-Diaminopyrimidines as inhibitors of Leishmanial and Trypanosomal dihydrofolate reductase Original Research Article
259
2,4-Diaryltetrahydropyran Formation by the Prins Cyclization and Its Application towards the Synthesis of Epicalyxin F and Calyxin I
260
2,4-Diazido-5-iodo-pyrimidine crystal under high pressure: A comparison of DFT and DFT-D studies
261
2,4-Dicarboxy-pyrroles as selective non-Competitive mGluR1 antagonists: further characterization of 3,5-Dimethyl pyrrole-2,4-dicarboxylic acid 2-propyl ester 4-(1,2,2-Trimethyl-propyl) ester and structure–Activity relationships
262
2,4-Dichlorophenol (DCP) containing wastewater treatment using a hybrid-loop bioreactor
263
2,4-Dichlorophenoxy acetic acid, abscisic acid, andhydrogen peroxide induced resistance-related components against potato early blight (Alternaria solani, Sorauer)
264
2,4-Dichlorophenoxyacetic acid (2,4-D) biodegradation in river sediments of Northeast-Scotland and its effect on the microbial communities (PLFA and DGGE)
265
2,4-Dichlorophenoxyacetic acid (2,4-D) sorption and degradation dynamics in three agricultural soils
266
2,4-dichlorophenoxyacetic acid adsorption from contaminated water through activated carbon reclaimed with zero-valent iron and titanium dioxide
267
2,4-Dichlorophenoxyacetic acid degradation by catalyzed ozonation: TiO2/UVA/O3 and Fe(II)/UVA/O3 systems
268
2,4-dichlorophenoxyacetic acid-induced leaf senescence in mung bean (Vigna radiata L. Wilczek) and senescence inhibition by co-treatment with silver nanoparticles
269
2,4-Dienoyl-CoA Reductase from Escherichia coli Is a Novel Iron–Sulfur Flavoprotein That Functions in Fatty Acid β-Oxidation
270
2,4-Dimethoxyphenylsemicarbazones with anticonvulsant activity against three animal models of seizures: Synthesis and pharmacological evaluation Original Research Article
271
2,4-Dimethylphenol imprinted polymers as a solid-phase extraction sorbent for class-selective extraction of phenolic compounds from environmental water
272
2,4-Dinitro-3,5,6-trideuterophenylhydrazones for the quantitation of aldehydes and ketones in air samples by liquid chromatography–mass spectrometry
273
2,4-Dinitrophenol adsorption by date seeds: Effect of physico-chemical environment and regeneration study Original Research Article
274
2,4-Dinitrophenol and Carbonylcyanide p-Trifluoromethoxyphenylhydrazone Activate the Glutathione S-Conjugate Transport ATPase of Human Erythrocyte Membranes
275
2,4-Dinitrophenol as an activating reagent in a facile preparation of cyclic phosphate triesters
276
2,4-Dinitrophenol reduces the reactivity of Lys553 in the lower 50-kDa region of myosin subfragment 1
277
2,4-Dinitrophenol: a novel activating reagent in nucleotide synthesis via the phosphoramidite route. Design of new effective phosphitylating reagents
278
2,4-Disubstituted oxazoles and thiazoles as latent pharmacophores for diacylhydrazine of SC-51089, a potent PGE2 antagonist Original Research Article
279
2,4-Disubstituted piperidines as selective CC chemokine receptor 3 (CCR3) antagonists: Synthesis and selectivity
280
2,4-Disubstituted pyrimidines: A novel class of KDR kinase inhibitors
281
2,4-Disubstituted pyrroles: synthesis, traceless linking and pharmacological investigations leading to the dopamine D4 receptor partial agonist FAUC 356
282
2,4-Disubstituted-5-acetoxythiazoles: useful intermediates for the synthesis of thiazolones and 2,4,5-trisubstituted thiazoles
283
2,4-thiazolidinediones as potent and selective human β3 agonists
284
2,5,7-Trisubstituted benzo[b]furans through a copper- and/or palladium-catalyzed assembly and functionalization process
285
2,5-Anhydro sugar diacid and 2,5-anhydro sugar diamine based C2 symmetric peptidomimetics as potential HIV-1 protease inhibitors
286
2,5-Bis(1,3-dithiol-2-ylidene)-1,3,4,6-tetrathiapentalene (TTP) derivatives having four long alkylthio chains
287
2,5-Bis-(2-hydroxybenzoylamino)pentanoic acid, a salicylic acid-metabolite isolated from chicken: characterization and independent synthesis
288
2,5-Bis-(butyltelluro) thiophene as a convenient precursor for the synthesis of 2,5-bis-(acetylenic) thiophenes
289
2,5-Bis(diphenylmethylene)-3-cyclopentenone: a solvent-dependent cobalt cluster mediated propargyl radical coupling process
290
2,5-Bis(pyridyl)pyrazine PtM, Pt2M and Ti2M2 transition metal complexes (M = Cu, Ag)
291
2,5-Bis-(sulfonyl)pyrazines as unprecedented building blocks and their SNAr reactions
292
2,5-Bis{N-(2,6-diisopropylphenyl)iminomethyl}pyrrolyl borohydride complexes of the divalent lanthanides – Synthesis, structures and ring-opening polymerization of ε-caprolactone
293
2,5-Deoxyfructosazine, a d-glucosamine derivative, inhibits T-cell interleukin-2 production better than d-glucosamine Original Research Article
294
2,5-di(thiophen-2-yl)thiazolo[5,4-d]thiazole-based donor–acceptor type copolymers for photovoltaic cells
295
2,5-Diamidofuran anion receptors
296
2,5-Diaminopyrimidines and 3,5-disubstituted azapurines as inhibitors of glycogen synthase kinase-3 (GSK-3)
297
2,5-Diarylisothiazolone: novel inhibitors of cytokine-induced cartilage destruction Original Research Article
298
2,5-Dichloro-1-(ROSO2)benzene [R = C6H5, C6F5, and CH2(CF2)4H]: Synthesis, molecular structure, and solubility in supercritical CO2
299
2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease Original Research Article
300
2,5-Difluoro-1,4-dimethoxybenzene for overcharge protection of secondary lithium batteries
301
2,5-Dihydropyrazolo[4,3-c]pyridin-3-ones: functionally selective benzodiazepine binding site ligands on the GABAA receptor
302
2,5-dihydroxybenzo-1,3,2-dithiazolylium and 2,7-dicarbonylnaphtha-1,3,2-dithiazolylium salts and their corresponding radicals Evolution of the pseudo-1,3-dipolar cycloaddition chemistry of SNSMF6(M = As, Sb) leading to
303
2,5-Diketopiperazines as potent and selective oxytocin antagonists 1: identification, stereochemistry and initial SAR
304
2,5-Dimethoxy-2,5-dihydrofuran and vinyl ethers in the synthesis of functionalised 2-alkylfurans
305
2,5-Dimethoxy-2,5-dihydrofuran chemistry: a new approach to 2(5H)-furanone derivatives
306
2,5-Dimethyl-4-hydroxy-2H-furan-3-one and its derivatives: analysis, synthesis and biosynthesis—a review
307
2,5-Di­methyl­bufo­tenine and 2,5-di­methyl­bufo­teni­dine: novel derivatives of natural tryptamines found in Bufo alvarius toads
308
2,5-Disubstituted 3,4-dihydro-2H-benzo[b][1,4]thiazepines as potent and selective V2 arginine vasopressin receptor antagonists
309
2,5-Disubstituted furans from 1,4-alkynediols
310
2,5-Disubstituted pyridines: The discovery of a novel series of 5-HT2A ligands
311
2,5-Disubstituted pyrrolidine carboxylates as potent, orally active sphingosine-1-phosphate (S1P) receptor agonists
312
2,5-Di-tert-butyl-1,4-hydroquinone enhances cell transformation accompanied by an increase in intracellular free calcium ion concentration
313
2,5-Hexanedione altered the degradation of low-molecular-weight neurofilament in rat nerve tissues
314
2,5-Pyridinedicarboxylic acid derivatives as non-Nucleosidic Reverse transcriptase inhibitors of Hepatitis B Virus
315
2,6,10,15,19-Pentamethylicosenes in Methanolobus bombayensis, a marine methanogenic archaeon, and in Methanosarcina mazei
316
2,6,10-Tris(bithiophenyl)triphenylene: Synthesis and high-spin alignment in its p-doped radical derivative
317
2,6,8,9-Tetrasubstituted Purines as New CDK1 Inhibitors
318
2,6,9-Trioxabicyclo[3.3.1]nona-3,7-dien-4-oyl and tetraoxaadamantan-9-oyl functionalized aromatic di- and triamines: synthesis, stereochemistry and complexation
319
2,6,9-trisubstituted purines : Optimization towards highly potent and selective CDK1 inhibitors
320
2,6-Anhydroaldonic acids; Methyl 2,6-anhydroaldonates; 2,6-Anhydroaldonamides; Anhydroalditols; Anhydrodeoxynitroalditols
321
2,6-Bis(2-benzimidazolyl)pyridine as a chemosensor for fluoride ions
322
2,6-Bis(2-benzimidazolyl)pyridine receptor for urea recognition
323
2,6-Bis(3,4,5-trihydroxybenzylydene) derivatives of cyclohexanone: novel potent HIV-1 integrase inhibitors that prevent HIV-1 multiplication in cell-based assays Original Research Article
324
2,6-Bis(5,6-dipropyl-1,2,4-triazin-3-yl)-pyridine: Structures of An(III) and Ln(III) 1:3 complexes and selectivity
325
2,6-Bis(benzoxazoyl)pyridine (bzpybox) as a new dialkylammonium cation receptor
326
2,6-Bis(diphenylphosphino)pyridine: a simple ligand showing high performance in palladium-catalyzed CN coupling reactions
327
2,6-Bis(porphyrin)-substituted pyrazine: a new class of supramolecular synthon binding to a transition-metal ion and fullerene (C60)
328
2,6-Cyclo-xenicanes from the brown algae Dilophus fasciola and Dilophus spiralis
329
2,6-Di(4-t-butylphenyl)phenyl-group 13 organometallic compounds
330
2,6-Di(pyrimidin-4-yl)pyridine Ligands with Nitrogen-Containing Auxiliaries: The Formation of Functionalized Molecular Clefts upon Metal Coordination
331
2,6-Diaryl-4-acylaminopyrimidines as potent and selective adenosine A2A antagonists with improved solubility and metabolic stability
332
2,6-Diaryl-4-phenacylaminopyrimidines as potent and selective adenosine A2A antagonists with reduced hERG liability
333
2,6-Diarylethynylanthracenes: synthesis, morphology, and electro-optical properties
334
2,6-Dibenzhydryl-N-(2-aryliminoacenaphthylenylidene)-4-chlorobenzenamino-palladium dichlorides: Synthesis, characterization, and use as catalysts in the Heck-reaction
335
2,6-Dibenzhydryl-N-(2-phenyliminoacenaphthylenylidene)-4-chloro-aniline nickel dihalides: Synthesis, characterization and ethylene polymerization for polyethylenes with high molecular weights
336
2,6-Dicarboxypyridinium chlorochromate: a mild, efficient, and selective reagent for oxidative deprotection of oximes to carbonyl compounds
337
2,6-Dicarboxypyridinium chlorochromate: an efficient and selective reagent for the oxidation of thiols to disulfides and sulfides to sulfoxides
338
2,6-Dichlorobenzonitrile, a cellulose biosynthesis inhibitor, affects morphology and structural integrity of petunia and lily pollen tubes
339
2,6-Difluorphenylxenon(II)bis(fluorsulfonyl)amid, -bis(trifluormethylsulfonyl)amid, -tris(fluorsulfonyl)methanid und -bis(trifluormethylsulfonyl)methanid—neue C–Xe–N- und C–Xe–C-Verbindungen?
340
2,6-Dimethoxyphenylphosphirane Oxide and Sulfide and their Thermolysis to Phosphinidene Chalcogenides—Kinetic and Mechanistic Studies
341
2,6-Dinitroaniline and β-cyclodextrin inclusion complex properties studied by different analytical methods
342
2,6-Diphenylphenolates of calcium, strontium and barium exhibiting π-phenyl encapsulation of the partially naked cations
343
2,6-Diphenylpyridine-based fluorophores: Synthesis, photophysical properties and effects of protonation
344
2,6-Diphenylpyridine-based organic emitter for electroluminescent device
345
2,6-Disubstituted N-arylsulfonyl piperidines as γ-secretase inhibitors
346
2,6-Disubstituted pyran-4-one and thiopyran-4-one inhibitors of DNA-Dependent protein kinase (DNA-PK)
347
2,6-Di-tert-butyl-4-diarylmethylene- 2,5-cyclohexadiene-1-thiones. First Isolable Unannelated Thioquinone Methides
348
2,6-pyridinedicarboxylic acid as an efficient and mild organocatalyst for the one-pot synthesis of xanthene derivative
349
2,6-Pyridinedicarboxylic acid as organocatalyst for the synthesis of 1,5-benzodiazepines through one-pot reaction
350
2,6-Quinolinyl derivatives as potent VLA-4 antagonists
351
2,7-Diazabicyclo[3.3.0]octanes as novel h5-HT1D receptor agonists
352
2,7-Dihydro-3H-pyridazino[5,4,3-kl]acridin-3-one derivatives, novel type of cytotoxic agents active on multidrug-resistant cell lines. Synthesis and biological evaluation Original Research Article
353
2,7-Dimethyl-3,8-dinitrodipyrazolo[1,5-a:1′,5′-d]pyrazine-4,9-dione: A new labelling reagent for liquid chromatographic analysis of amino acids Original Research Article
354
2,7-Disubstituted proton sponges as borderline systems for investigating barrier-free intramolecular hydrogen bonds. Protonated 2,7-bis(trimethylsilyl)- and 2,7-di(hydroxymethyl)-1,8-bis(dimethylamino)naphthalenes
355
2,7-Di-tert-butyl-Fmoc-P-OSu: A new polymer-Supported reagent for the protection of the amino group
356
2,8-Disubstituted adenosine derivatives as partial agonists for the adenosine A2A receptor Original Research Article
357
2,9-Dibromopentacene: Synthesis and the role of substituent and symmetry on solid-state order
358
2,9-Disubstituted-N6-(arylcarbamoyl)-8-azaadenines as new selective A3 adenosine receptor antagonists: Synthesis, biochemical and molecular modelling studies Original Research Article
359
2,μ(Ω) estimate to the mixed boundary value problem for second order elliptic equations and its application in the thermistor problem Original Research Article
360
2. A randomized, double-blind, multicentre crossover trial to evaluate in vivo inhibition of aromatase by Arimidex (ZD1033) (1 mg and 10 mg PO OD) in postmenopausal women with breast cancer
361
2. Changes in short afferent inhibition during phasic movement in focal dystonia
362
2. Comparison of the disinfection by-product formation potentials between a wastewater effluent and surface waters
363
2. Development and testing of an iPad application for teaching self-management to heart failure patients
364
2. Development of interictal spikes following status epilepticus from intrahippocampal pilocarpine
365
2. Dynamic analysis of EEG/MEG signals combined with fMRI
366
2. Economic assumptions underlying asian energy markets
367
2. Numerical Simulations of Water Flow and Solute Transport Applied to Acid Sulfate Soils
368
2. Pre-operative education – a review of the research design
369
2. Prognostic factors for the classification and staging of breast cancers
370
2. Receptors in HDL metabolism
371
2. Sensitized degradation of chlorophenols on iron oxides induced by visible light: Comparison with titanium oxide
372
2. Sex and intimacy among patients with implantable left-ventricular assist devices
373
2. Sleep-disordered breathing in heart failure; developing an evidence-based screening protocol
374
2. Somatosensory-evoked potential in patients with amyotrophic lateral sclerosis in a totally locked-in state
375
2. The influence of physical symptoms and mild cognitive impairment on heart failure self care
376
2. The IPC during the third revision period and beyond
377
2. THE RECONFIGURATION OF WORK AND EMPLOYMENT RELATIONS IN THE UNITED STATES AT THE TURN OF THE CENTURY
378
2. The response of a laboratory stream system to PCB exposure: study of periphytic and sediment accumulation patterns
379
2. The relationship between the satellite-based index and standard precipitation index, on different land covers
380
2.0 Å Resolution Crystal Structures of the Ternary Complexes of Human Phenylalanine Hydroxylase Catalytic Domain with Tetrahydrobiopterin and 3-(2-Thienyl)-l-alanine or l-Norleucine: Substrate Specificity and Molecular Motions Related to Substrate Binding
381
2.1 Maintaining walking direction when combining gaitwith vision distraction in young and elderly
382
2.1. Laboratory investigations in trigeminal neuralgia
383
2.10 Walking is more like catching than tapping: gait in the elderly as a complex cognitive task
384
2.11 A prospective study of older adults with a high level gait disorder: Evidence for a neurodegenerative process
385
2.1–1.85 Ga tectonic events in the Yangtze Block, South China: Petrological and geochronological evidence from the Kongling Complex and implications for the reconstruction of supercontinent Columbia
386
2.12 Gaze position, distance and postural stability in young and old subjects
387
2.13 Visual context affects postural strategies in healthy and labyrinthine deficient elderly
388
2.14 Effect of tactile ground surface indicators to the gait of elderly with normal vision
389
2.15 Age related changes in coping strategies to posturalthreat
390
2.16 Dynamic electromyographic activities of lower extremity muscles in patients with osteoarthritis of the knees
391
2.17 Dynamic control strategies used by older adults during obstacle avoidance
392
2.18 Center of mass (CoM) kinematics at slip onset and slip severity
393
2.19 The effect of age on dynamic postural equilibrium when stepping up
394
2.2 Performance based and self-reported postural control and functional correlates of stair climbing capacity
395
2.2. Spinothalamic nociceptive pathways
396
2.20 The role of vision in static posture control is age and task-dependent
397
2.21 Effects of protective equipment on the balancecontrol among younger and older firefighters
398
2.22 Postural balance in female and male subjects aged 8 to 93 years: A cross-sectional comparison
399
2.23 Effects of exercise and nutrition on Romberg quotient of postural balance in elderly with decreased bone mineral density
400
2.23 W diode-pumped Nd:YVO4/LBO Laser at 671 nm
401
2.24 The effect of postural sway on responses to anunexpected perturbation in young and elderly adults
402
2.25 Kinematic synergy adaptation to an unstable support surface and equilibrium maintenance in aging adults
403
2.26 The passive forward-push test can determine postural strategies
404
2.27 Controlling stability in challenging environments:Effects of ageing on modulation of rapid stepping reactions
405
2.28 Gaze behavior and the modulation of triggered stepping reactions to meet environmental demands in older adults
406
2.3 Vision influences on postural stability in different ages
407
2.3. Long-term depression of orofacial somatosensory processing
408
2.36 (mu)m diode pumped VCSEL operating at room temperature in continuous wave with circular TEM/sub 00/ output beam
409
2.4 GHz continuously variable ferroelectric phase shifters using all-pass networks
410
2.4 GHz direct-digital binary phase shift keying modulator using MEMS switch
411
2.4 Improving balance through imagery in frail elderly: Apilot study
412
2.4. Blink reflexes in orofacial pain conditions
413
2.41 W compact efficient CW blue light generation by intra-cavity frequency doubling of a compact Nd:YAG laser
414
2.45 GHz microwave plasma system for high-velocity thermal spraying
415
2.45 GHz synchronised polarised electron injection at MAMI
416
2.45 GHz synchronised polarised electron injection at MAMI
417
2.45-GHz-CMOS temperature compensated multi-controlled oscillator for IEEE 802.15 wireless PAN
418
2.4-in. monochrome small molecular OLED display for mobile application
419
2.5 BILLION LIVE WITH POOR SANITATION FACILITIES
420
2.5 Gbit/s silicon receiver OEIC with large diameter photodiode
421
2.5 GHz BaTiO3 DIELECTRIC RESONATOR ANTENNA
422
2.5 Kinematic and electromyographic analysis of rising from a chair during a “sit-to-walk” task in elderly subjects
423
2.5 MeV electron irradiation effect of alumina ceramics
424
2.5. The trigemino facial inhibitory reflex: Physiology, recording technique and topodiagnostic use
425
2.56-Tb/s (64*42.7 Gb/s) WDM transmission over 6000 km using all-Raman amplified inverse double-hybrid spans
426
2.5D Elastic graph matching
427
2.5D face recognition using Patch Geodesic Moments
428
2.5-D frequency-domain seismic wave modeling in heterogeneous, anisotropic media using a Gaussian quadrature grid technique
429
2.5-D gravity model of the Ni---Cu---PGM mineralized Mount Ayliff Intrusion (Insizwa Complex), South Africa
430
2.5-D Modeling in electromagnetic methods of geophysics
431
2.5D modelling of Somma–Vesuvius structure by aeromagnetic data
432
2.5-D Numerical Simulation of Acoustic Wave Propagation
433
2.5D scattering of waves by rigid inclusions buried under a fluid channel via BEM
434
2.5-Year-olds use cross-situational consistency to learn verbs under referential uncertainty
435
2.6 Å Resolution Crystal Structure of Helices of the Motile Major Sperm Protein (MSP) of Caenorhabditis elegans
436
2.6 The elderly combat to strive for better physical health
437
2.6. The role of the brain stem in central sensitisation in humans
438
2.61 (mu)m GaInAsSb/AlGaAsSb type I quantum well laser diodes with low threshold
439
2.61 Ga potassic granites and crustal reworking in the western Dharwar craton, southern India: Tectonic, geochronologic and geochemical constraints
440
2.7 Effect of age on movement amplitude and frequencyduring heel-toe rocking
441
2.7 μm fluorescence and energy transfer in Er3+ doped germanosilicate glasses
442
2.7. Bilateral brainstem activation by noxious thermal stimulation in the face
443
2.8 Å crystal structure of the malachite green aptamer
444
2.8 Challenges to whole-body stability during turning in older adults
445
2.8 Ga Old Anorogenic Granite-Acid Volcanics Association from Western Margin of the Singhbhum-Orissa Craton, Eastern India
446
2.85 µm fluorescence of Ho-doped water-free fluorotellurite glasses
447
2.9 Functional capacities evaluation during simulate working task
448
2.C.4 Dietary fatty acids and the prevention of cardiovascular disease
449
2.C.6 New strategies for drugs in atherosclerosis
450
2.E.1 Fish oil, lipids and coronary disease
451
2.Endothelin antagonists: Evaluation of 2,1,3-benzothiadiazole as a methylendioxyphenyl bioisoster
452
2.P.1 Selective uptake of HDL-CE by human adipose tissue is an LRP-dependent process
453
2.P.10 Effects of erythromycin on plasma fluvastatin levels: A pharmacokinetic study
454
2.P.100 The in vivo of metabolism of free-Apo(a) in normals and subjects with abetalipoproteinemia
455
2.P.101 Effect of gamma radiolysis-induced oxidation of lipoprotein(a) on plasminogen activator inhibitor (PAI-1) secretion by endothelial
456
2.P.102 Nicotinic acid decreases specifically plasma Lp(a) in cynomolgus monkeys without affecting other lipoproteins
457
2.P.103 Immunoquantification of lipoprotein (a): A comparative evaluation of four methods
458
2.P.104 Effect of continuous combined estrogen-progestin therapy on lipoprotein (a) and lipid metabolism
459
2.P.105 Apo (a) phenotypes and Lp(a) levels in acute coronary syndromes
460
2.P.106 Lp(a) and cholesterol act synergistically and predict primary myocardial infarction in Swedish males
461
2.P.107 The importance of Lp(a) as a risk factor for coronary heart disease in black and white US women
462
2.P.108 Effects of losartan on blood pressure, microalbuminuria, insulin sensitivity and lipid profile in hypertensive type II diabetics with microalbuminuria
463
2.P.109 Lack of effect of acute and chronic normalization of plasma growth hormone concentration on lipoprotein (a) levels in patients with acromegalia
464
2.P.11 Effects of atorvastatin on intracellular levels and stability of apolipoprotein B and HMG-CoA reductase in Hep G2 cells
465
2.P.110 Reduction of Lp(a) by LDL-immunoadsorption
466
2.P.111 Elevated lipoprotein (a) levels and coronary heart disease: Differences between non-insulin-dependent diabetic patients and nondiabetic subjects
467
2.P.112 Urinary excretion of lipoprotein(a) and apolipoprotein(a) in nephrotic patients
468
2.P.114 Lp(a) levels in patients with mild/moderate renal failure
469
2.P.115 Apolipoprotein(a) phenotypes as a predictor of occlusions in coronary arteries
470
2.P.116 Alcohol consumption, lipoprotein(a) and hormonal status in middle-aged black African males
471
2.P.117 Is the measurement of unbound apo(a) of diagnostic interest?
472
2.P.118 The impact of heat shock proteins as a risk factor for coronary heart disease
473
2.P.119 The KIV-10 Asp57 → Thr mutation in chimpanzee apo(a) abolishes fibrin binding
474
2.P.12 Inhibitors of hydroxymethyl glutaryl-CoA reductase as modulators of intimal thickening in diet-induced atherosclerosis
475
2.P.120 Identification of kringles of apolipoprotein(a) that enable its binding to fibrin and monocytic cells
476
2.P.121 Binding of apo(a) isoforms to fibrin is modified by their incorporation into an LDL lipoparticle
477
2.P.122 Elevated level of lipoprotein(a) and severity of coronary artery disease in non-diabetic patients
478
2.P.123 Treatment of hyperlipoproteinemia (a) with LDL-apheresis in order to stop progredient coronary heart disease: A case report
479
2.P.124 Effectiveness of the whole blood adsorber system dali in the treatment of hyperlipoproteinemia(a)
480
2.P.125 The effects of body weight loss on lipoprotein(a) in obese Japanese middle-aged women
481
2.P.126 Studies of the 5′-region of the apolipoprotein(a) gene in HepG2 cells by luciferase reporter gene assays
482
2.P.127 Red wine consumption: Another antiatherogenic effect related to decreased lipoprotein(a) levels
483
2.P.128 Recombinant apolipoprotein(a) and lipoprotein(a) enhance platelet responses to a thrombin receptor-activating peptide
484
2.P.129 Urinary excretion of apo(a) fragments in non insulin dependent diabetes mellitus patients
485
2.P.13 Effect of lovastatin in hyperlipoproteinaemic patients
486
2.P.130 Urinary excretion of apo(a) in patients after kidney transplantation
487
2.P.131 Demonstration of covalent binding of lipoprotein(a) [Lp(a)] to fibrin and human umbilical vein endothelial cells (HUVEC)
488
2.P.132 A fibrin-binding method for the functional identification of lipoprotein(a) in plasma from patients with cardiovascular disease
489
2.P.133 Lp(a) levels and apo(a) phenotypes in angiographically established coronary heart disease and in controls
490
2.P.134 Synthetic regulation of lipoprotein(a) in monkey hepatocytes
491
2.P.136 Serum lipoprotein(a) and ultrasonographic findings of carotid plaques
492
2.P.137 Increased degradation of lipoprotein(a) in atherosclerotic compared with nonlesioned aortic intima-inner media: In vivo evidence that lipoprotein(a) may contribute to foam cell formation
493
2.P.138 Increased levels of Lp(a) in nephrotic syndrome of children is related to hypoalbuminemia, not to proteinuria
494
2.P.139 Effects of oral isotretinoin (13-cis retinoic acid) on lipoprotein(a) and HDL subclasses lpA-I and lpA-I: A-II in healthy volunteers
495
2.P.14 An overview of the clinical safety profile of atorvastatin a new, more effective HMG-CoA reductase inhibitor
496
2.P.140 Lp(a) secretion is enhanced by incubation of cynomolgus monkey hepatocytes with retinoic acid
497
2.P.141 Screening for mutations in the apolipoprotein(a) unique kringles type 6, 9 and 10
498
2.P.142 Prevalence of atherosclerotic vascular disease in the pedigrees with high Lp(a)
499
2.P.143 Lipoprotein (a) metabolism in patients with heterozygous familial hypercholesterolemia
500
2.P.144 Lp(α) levels during acute infections
501
2.P.145 Lipoprotein(a) concentration and apolipoprotein(a) isoform size in young patients with stroke
502
2.P.146 Differentiation of plasma lipoprotein (a) in a population of 1989 Greek army recruits
503
2.P.147 Lp(a) apheresis new approach for specific Lp(a) lowering
504
2.P.148 Lp(a) levels in an heterogeneous sample of subjects with familial hypercholesterolemia
505
2.P.149 Uptake of lipoprotein(a) by mouse embryonic fibroblasts via the LDL-receptor and/or the LDL receptor-related protein
506
2.P.15 Two-year comparison of safety and efficacy of atorvastatin and lovastatin
507
2.P.150 The carotid artery stenosis and the Lp(a) serum concentration: A correlation analysis
508
2.P.151 Lipoprotein(a) concentrations in subjects with one and two apolipoprotein(a) isoforms
509
2.P.152 Physical exercise decreases lipoprotein(a) levels in hyper-lp(a) diabetic patients
510
2.P.154 Lack of impaired endothelium-dependent vasorelaxation in aortas isolated from transgenic mice expressing human apolipoprotein(a)
511
2.P.155 Cholesterol esterification in hypercholesterolemic and normolipidemic subjects: Effects of simvastatin
512
2.P.156 Lipoprotein(a) levels in pulmonary arterial hypertension
513
2.P.157 Apolipoprotein(a) phenotype and serum Lp(a) levels in patients with angina pectoris and myocardial infarction
514
2.P.158 The effects of Lipoprotein (a) on endothelial function
515
2.P.159 The role of Lp(a) in the development of coronary artery disease seems to be age dependent
516
2.P.16 Fluvastatin inhibits free radical-initiated oxidation of LDL and erythrocyte hemolysis in vitro
517
2.P.160 A comparison of lipoprotein (a)-cholesterol levels and sinking prebeta lipoprol with heart disease risk in the Framingham heart study
518
2.P.161 Effect of glyated lipoprotein(a) on the production of fibrinolytic regulators in vascular endothelial cells
519
2.P.162 Relation of 5′-flanking region of the apolipoprotein(a) gene to serum lipoprotein(a) level
520
2.P.163 Localization of Lp(a) gene in human chromosomes by in situ hybridization with digoxigenin-labeled probe
521
2.P.164 Transcriptional regulation of apolipoprotein(a) synthesis by insulin
522
2.P.165 Lipoprotein(a) is a potent chemoattractant selective for human peripheral monocytes
523
2.P.166 Elevated lipoprotein(a) levels in patients with myocardial infarction are not fully determined by variation at the apo(a) gene locus. The ECTIM study
524
2.P.167 Discrepancy between whole blood and plasma concentrations of Lp(a)
525
2.P.168 Low HDL cholesterol and low lipid standardized vitamin E are the best determinants of lipid risk in our coronary patients
526
2.P.169 Detection of serum lipoprotein(a) by agarose gel electrophoresis
527
2.P.17 Effectiveness of atorvastatin in treating patients to LDL-C goals compared with lovastatin, pravastatin and simvastatin
528
2.P.170 Nandrolone decanoate reduces lipoprotein(a) levels without effect on other lipid parameters
529
2.P.171 Effect of repeated Lp(a) apheresis on metabolic parameters of lipoprotein(a)
530
2.P.172 Effect of dietary pattern on serum lipoprotein parameters in young families
531
2.P.173 Evaluation of the risk factors in coronary artery disease in Egypt. Evolving data from the national project: Lipid Profile among Egyptians (L.P.E)
532
2.P.174 Apolipoproteins and lipoprotein particles level in Moroccan patients with previous myocardial infarction
533
2.P.175 Carotid atherosclerosis and vascular risk factors in patients attending an Italian Lipid Clinic
534
2.P.176 Management of low-density lipoprotein cholesterol for secondary prevention of cardiac event after myocardial infarction
535
2.P.177 High level homocysteine, LDL modification and CHD
536
2.P.178 Smoking and transvascular leakage of albumin: Preliminary findings
537
2.P.179 Towards a cellular basis for mild hyperhomocysteinemia: Methionine metabolism in cultured human peripheral blood cells
538
2.P.18 Comparison of the efficacy and safety of atorvastatin with simvastatin in patients with primary hypercholesterolemia
539
2.P.180 Prognostic value of raised soluble thrombomodulin and soluble E-selectin in ischaemic heart disease
540
2.P.181 Lipids atherogenic factors in patients on haemodyalysis
541
2.P.182 Low density lipoprotein-associated phospholipase A2 (LDL-PLA2) as a risk factor for coronary artery disease
542
2.P.183 Microalbuminuria in dislipidaemic subjects
543
2.P.184 Fibrinolytic parameters and insulin sensitivity index related to fasting and postprandial triglyceride (TG) in healthy “normolipemic” subjects
544
2.P.185 Coronary heart disease risk factor clustering among three French regions: The WHO-MONICA population study
545
2.P.186 Influence of endurance training on susceptibility of LDL to oxidation
546
2.P.187 Methylenetetrahydrofolate reductase gene and carotid artery structural and functional characteristics in asymptomatic subjects
547
2.P.188 Pro-thrombotic effects of an acute methionine load-induced hyperhomocysteinemia in rats
548
2.P.189 Hyper-HDLemia in renal transplant recipients: Mechanisms and significations
549
2.P.19 The short-term effects of atorvastatin on lipid levels in patients with hyperlipidemia
550
2.P.190 Dyslipidaemias in children and adolescents in Portugal: A public health problem
551
2.P.191 Lipoproteins and homocysteine as risk markers for mortality in patients with coronary artery disease (CAD)
552
2.P.192 Lack of adequate risk factor management in patients with coronary artery disease
553
2.P.193 The current management of cardiovascular risk factors does not match the severity of risk factors and clinical guidelines
554
2.P.194 Coronary risk profile in Brazil
555
2.P.195 Gender differences in prediction of coronary artery disease (CAD) by plasma lipoproteins, LCAT measurements
556
2.P.196 LP(a), PAI-1 and fibrinogen are predictors of severe carotid atherosclerosis in young individuals
557
2.P.197 How many patients with coronary artery disease exhibit a significant lipid disorder in a department of cardiology in France?
558
2.P.198 Sitostanol ester added to long term simvastatin treatment of coronary patients with low and high basal cholesterol absorption
559
2.P.199 Significance of insulin like growth factor 1 for macro- and microangiopathy in non-insulin-dependent diabetes mellitus
560
2.P.2 The composition and structure of HDL regulate plasma clearance kinetics in rabbits
561
2.P.20 HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit atherosclerotic lesion formation in the rabbit
562
2.P.201 Does the fitness influence plasma lipoprotein levels?
563
2.P.202 Correlation between the concentrations of plasma homocysteine and vitamin B6, B12, and folate in end stage renal disease
564
2.P.203 Relation of cigarette smoking to other cardiovascular risk factors in the general population of Singapore
565
2.P.204 Homocysteine, recurrent cardiac events, and the methylenetrarahydrofolate thermolabile mutation in coronary artery disease patients
566
2.P.205 The assessment of determinants of cardiovascular risk factor clustering by multiple regression analysis
567
2.P.206 Hyperhomocysteinaemia attributes to 10 percent of all cardiovascular disease in a 50–75 year-old Caucasian population
568
2.P.207 Elevated levels of plasma homocysteine related to atherosclerotic lesions of vein grafts after coronary artery bypass grafts (CABG)
569
2.P.208 Associations between triglycerides and cholesterol levels and myocardial infarction: Results of the Tunisian study
570
2.P.21 The HMG-CoA reductase inhibitors atorvastatin and lovastatin reduce accumulation of collagenase and 92-kD gelatinase released by cultured human monocytic and vascular smooth muscle cells
571
2.P.210 Family screening as an effective tool to prevent early cardiovascular events
572
2.P.211 Plasma homocysteine levels and premature coronary artery disease in male patients
573
2.P.212 Short stature and heart disease: Nature or nurture?
574
2.P.213 Age-trends of lipid profile in Novosibirsk population
575
2.P.214 Lipid and hemostatic risk factors of coronary insufficiency in syndrome X
576
2.P.215 Hyperinsulinemia and cardiovascular mortality
577
2.P.216 To assess the changes in cardiovascular risk profile after one year of intervention at a worksite
578
2.P.217 MTHFR thermolability and vitamin status in the pathogenesis of hyperhomocysteinemia in coronary artery disease subjects
579
2.P.218 Is a fasting plasma homocysteine measurement an adequate screen for hyperhomocysteinemia?
580
2.P.219 Homocysteine and carotid artery atherosclerosis
581
2.P.22 Efficacy and safety of fluvastatin in patients with non insulin dependent diabetes on insulin therapy and dyslipidemia
582
2.P.220 Serum fibrinogen and lipoprotein(a) in a Portuguese NIDDM population
583
2.P.222 Coronary heart disease risk factors and carotid atherosclerosis in a high risk Hungarian population
584
2.P.223 Hyperfibrinogenemia and hypertriglyceridemia influence the histocytologic composition of atherosclerotic carotid plaques
585
2.P.224 Hyperhomocyst(e)inemia as an emerging risk factor of atherosclerotic vascular diseases
586
2.P.225 Effect of vitaminic therapy in hyperhomocysteinemic patients
587
2.P.226 Serum lipids in hyperhomocysteinemic patients
588
2.P.227 Frequencies of factor VII gene polymorphism and the relation to serum triglycerides in patients with chronic disease
589
2.P.228 Characteristics changes in coronary artery in patients with hypothyroidism and myocardial infarction
590
2.P.229 Hyperhomocysteinemia is a risk factor for ischemic heart disease in diabetic patients
591
2.P.23 A comparative study on the effects of fluvastatin and simvastatin on serum lipoproteins in hypercholesterolemic patients
592
2.P.230 Fractional esterification rate of cholesterol in HDL can predict the particle size of LDL and HDL in CHD patients
593
2.P.232 Lipids, LP(α) and fibrinogen in acute stroke episodes
594
2.P.233 Oxygen free radicals generation by granulocytes of patients with atherosclerosis
595
2.P.234 Risk factors for thoracic aortic atherosclerosis. A prospective study using multiplane transoesophageal echocardiography
596
2.P.235 Serum paraoxonase activity and early atherosclecrosis in hypertensive and hypercholesterolemic patients
597
2.P.236 A gas chromatography/mass spectrometry method for the quantitation of total homocysteine in human plasma
598
2.P.237 Cardiovascular risk factors in peripheral arterial disease patients with and without previous history of coronary artery disease
599
2.P.239 Lp(a) as a possible biochemical marker for vein graft stenosis after coronary artery bypass surgery
600
2.P.24 Responses to the inhibition of HMG-CoA reductase: A comparison of simvastatin and atorvastatin
601
2.P.240 Coronary heart disease risk in middle aged population - 10 year Warsaw Pol-MONICA follow-up project
602
2.P.241 Dependence between the advancement of the ischemic heart disease and the HDL cholesterol subfraction
603
2.P.243 Self-reported physical activity in healthy children is correlated with cardiovascular risk factors
604
2.P.244 Relatinship between plasma endothelin-1, HDL-C and systolic blood pressure in renal transplant recipients
605
2.P.245 Prospective randomized atherosclecrosis intervention trial in children The STRIP project
606
2.P.246 Methylentetrahydrofolate reductase genotypes in young survivors of myocardial infarction
607
2.P.247 Insulin resistance and homocystein - is there any relationship?
608
2.P.248 A prospective study of lipoprotein factors in patients with unstable angina and acute myocardial infarction
609
2.P.249 Lipoprotein metabolism in patients with coronary artery disease and its relationship with myocardial infarction
610
2.P.251 Coronary risk factors in subjects with familial hypercholesterolemia in Spain
611
2.P.252 HDL-cholesterol after surgery for aorto-coronary grafts
612
2.P.253 Common risk factors of atherosclerosis are independent from the insertion/deletion angiostensin converting enzyme gene polymorphism in subjects with coronary heart disease and healthy controls
613
2.P.254 Changes of lipid levels in Korean population
614
2.P.255 Atherosclerosis risk factors and nutrition of male students with the paternal premature myocardial infarction
615
2.P.256 Comparison of Brazilian men and women at high risk of vascular disease
616
2.P.257 Sensitivity of platelets to nitrix oxide is attenuated after vigorous exercise
617
2.P.259 Attitudes towards coronary risk factor reduction: The HELP study
618
2.P.26 Efficacy and safety of one-year treatment with slow-release nicotinic acid. Monitoring of drug concentration in serum
619
2.P.260 Independent effect of hyperglycaemia on coronary heart disease mortality among non-insulin dependent diabetic subjects: The Reykjavik study
620
2.P.261 The importance of lipid status in coronary heart disease
621
2.P.262 The assessment of risk of myocardial infarction in Moscow population
622
2.P.263 Twenty years lasting interventional study of cardiovascular risk factors in middle age men
623
2.P.264 A common mutation in methylenetetrahydrofolate reductase: Associations with homocysteine and risk of coronary atherosclerosis
624
2.P.265 Effects of androgenic anabolic steroids (AAS) on apolipoproteins and lipoprotein(a)
625
2.P.266 Serum angiotensin convertase activity in men after myocardial infarction and their healthy sons
626
2.P.268 Aging, smoking and hypercholesterolaemia have a less impact on endothelial function in the Chinese than Caucasian
627
2.P.269 Higher 7β-hydroxycholesterol in high cardiovascular risk population
628
2.P.27 Regulation of the growth kinetics of a promyelocitic leukemia cell line by hydroxymethyl glutaryl CoA-reductase
629
2.P.270 Lower oxidizability of LDL in elderly subjects with no evidence of carotid atherosclerosis
630
2.P.271 High plasma Lp(a) levels and low plasma HDL-cholesterol levels as risk factors for cerebrovascular disease in elderly men and women
631
2.P.272 Genetic risk factors in the elderly: Studies in the apolipoprotein E gene and in the methylenetetrahydrofolate reductase gene
632
2.P.273 The importance of hyperhomocysteinemia in high age people
633
2.P.275 Secondary prevention is the main basis of elderly referrals to a lipid clinic
634
2.P.276 Polymorphism of ApoAIV, apo(a) and Lp(a) plasma levels in centenarians
635
2.P.276 Polymorphism of ApoAIV, apo(a) and Lp(a) plasma levels in centenarians
636
2.P.277 One year experience with simvastatin in patients over 65 with primary hypercholesterolemia
637
2.P.278 Mild hyperhomocysteinemia correlated to folate status in Italian centenarians
638
2.P.279 Cardiovascular risks factors in a Pireness geriatric population
639
2.P.28 Preclinical drug metabolism studies in rat, mouse, dog and monkey with allometric scaling for CP-340,868, a novel squalene synthetase inhibitor
640
2.P.280 Serum sialic acid in elderly
641
2.P.285 Effects of the hormonal replacement therapy on plasma lipids in postmenopausal women with type II hyperlipidemia
642
2.P.286 Rationale and design of a trial to evaluate the impact of continuous combined hormone replacement therapy on the cardiovascular disease risk profile
643
2.P.287 Homocysteine is an independent determinant of plasma endothelin levels in healthy postmenopausal women
644
2.P.288 Postmenopausal increment of free and esterified cholesterol in the intima media of uterine arteries
645
2.P.289 Hormone replacement therapy: Can usage influence clinical outcome following coronary balloon angioplasty?
646
2.P.29 Effect of fluvastatin on plasma free-oxygen radicals (FOR) concentrations and on lipidaemic profile in patients with coronary artery disease (CAD)
647
2.P.290 Changes of lipid levels with menopause in women
648
2.P.291 Effects of tibolone on lipoproteins
649
2.P.292 The influence of menopause on LDL-subclass distributions, LDL-oxidizability and Lp(a) concentrations
650
2.P.293 Menopause aggravates postprandial lipemia
651
2.P.294 Effects of soy on lipoproteins in postmenopausal women: A double blind, multicentre, placebo-controlled trial
652
2.P.295 Does early menopause affect the risk of atherosclerosis?
653
2.P.296 The effect of hormone replacement therapy on hemostatic parameters in peri- and postmenopausal women
654
2.P.297 Lipid effects of adding C-19 versus C-21 progestin to conjugated estrogen in postmenopausal women
655
2.P.298 Current state of serum lipid levels in the general Japanese population - cholesterol and lipoprotein(a)
656
2.P.299 Effects of tamoxifen on lipid profile in postmenopausal women
657
2.P.3 Lipid-free apolipoprotein A-I can act as a shuttle to promote cholesterol efflux to apolipoprotein A-I-containng lipoproteins
658
2.P.30 Effect of fluvastatin on coagulant-fibrinolytic system in patients with coronary artery disease
659
2.P.300 Social strata and menopause caused changes in the cardiovascular risk profile
660
2.P.301 Estrogen/progestine replacement therapy improves the course of coronary artery disease in menopausal women
661
2.P.302 Smaller LDL particle size in women with polycystic ovary syndrome as compared to controls
662
2.P.303 Serum lipoprotein profile in women with coronary heart disease
663
2.P.304 17 β estradiol retard the progression of severe atherosclerosis induced by high cholesterol diet plus baloon injury: The relation of NO
664
2.P.305 Preliminary analysis of tamoxifen-induced lipemia
665
2.P.306 Hypercholesterolemia in the middle-age woman is individually a cause of ventricular arrhythmia
666
2.P.307 Gender does not predict adverse acute outcome following coronary balloon angioplasty
667
2.P.308 Lipoprotein(a), apolipoprotein E and hormonal profile in menstruating women after myocardial infarction
668
2.P.309 Effects of female sexual hormones on contractility and morphology of pre- and postmenopausal human uterine arteries
669
2.P.31 Reduction of egg yolk cholesterol content through inhibition of hepatic cholesterol biosynthesis and alteration of plasma VLDL composition in laying hens: Comparative effects of atorvastatin, lovastatin, and simvastatin
670
2.P.310 The evaluation of the atherogenic risk factors in pregnant women
671
2.P.311 Endogenous sex hormones and carotid atherosclerosis in women participating to a population-based study: Findings from Progetto Atena
672
2.P.312 Nitric oxide bioactivity in premenopausal women on hormonal contraceptives
673
2.P.313 The effect of raloxifene on markers of cardiovascular risk in healthy, post-menopausal women
674
2.P.314 Platelet aggregation induced by a monoclonal antibody to von Willebrand Factor
675
2.P.315 Simvastatin effect on platelet activity in patients with familial hypercholesterolaemia
676
2.P.316 Flow cytometry analysis of platelets in whole blood from unstable angina patients
677
2.P.317 Platelet size, β-thromboglobulin and serotonine concentration in patients with essential hypertension
678
2.P.318 Platelets count, morphology and aggregation in patients with familian hypercholesterolaemia
679
2.P.319 Effects of normothermic versus hypothermic cardiopulmonary bypass on cytokine production and platelet function
680
2.P.32 Comparison of cerivastatin and gemfibrozil in the treatment of primary mixed hyperlipidemia
681
2.P.320 Alkyl phosphatidylcholine core aldehydes exist in human atheromas and induce platelet aggregation through PAF receptor
682
2.P.321 Smoking, platelets and risk of thrombosis
683
2.P.322 The influence of butter and vegetable oil loadings on the state of thrombocyte membranes in patients with ischemic heart disease (IHD)
684
2.P.323 Structural and functional organisation of thrombocyte membranes in patients with ischemic heart disease (IHD) depending on menʹage
685
2.P.324 Immunolocalization of blocked and unblocked GP IIb-IIIa complexes in platelets during antithrombotic therapy with c7E3 Fab (ReoPro, abciximab)
686
2.P.325 CD36 is a specific platelet receptor for native and modified low-density lipoproteins
687
2.P.326 Short-term heterologous desensitization of platelet LDL receptor by high lipoprotein levels
688
2.P.326 Thyroid hormones as a determinant of plasma D-dimers levels in hyperlipidemic patients
689
2.P.327 Platelet αIIb-β3 integrin or glycoprotein (GP) IIb-IIIa complex are not related to platelet HDL3 binding
690
2.P.328 Long-term desensitization of platelet LDL receptor by high VLDL levels. Effects of gemfibrozil treatment
691
2.P.329 Hydrogen peroxide involvement in platement activation induced by collagen
692
2.P.33 Long-term extension of the comparison of cerivastatin and gemfibrozil in the treatment of primary mixed hyperlipidemia
693
2.P.330 Platelet behavior in whole blood with enhanced HDL concentration
694
2.P.331 The ADP-activated non selective cation channels may have a role in platelet aggregation
695
2.P.332 Relationship between reduction of plasma cholesterol and increased platelet activity in hypercholesterolemia
696
2.P.333 Evidence for th erole of adenosine diphosphate in platelet aggregation by remnant like lipoprotein particles of human plasma very low density lipoproteins and chylomicrns
697
2.P.334 ADP induces transient refractoriness of platelet adhesion to subendothelium under flow conditions
698
2.P.335 Colony-forming units-megakaryocytes (CFu-MEG) and primary hyperlipidemia
699
2.P.336 Native microaggregates and spontaneous platelet aggregation may present a platelet susceptibility leading to thrombogenesis - detection with an original method using a novel platelet aggregometer employing a laser light scattering
700
2.P.337 Secretion of PAF-acetylhydrolase activity during platelet aggregation in patients undergoing coronary angioplasty
701
2.P.338 Role of homocyst(e)ine in platelet aggregation
702
2.P.339 Impaired inhibition by insulin of ADP-induced expression of platelet fibrinogen receptor in NIDDM patients
703
2.P.34 Long-term efficacy and safety of a combined fluvastatin-fenofibrate therapy in primary hypercholesterolemia
704
2.P.340 Inhibition of the procoagulant activity of thromboplastin by apolipoprotein B-100
705
2.P.341 Effect of dietary saturated, oleic and n-3 fatty acids on acute collagen-induced thrombus formation in rats
706
2.P.342 Effect of policosanol on platelet aggregation and serum levels or arachidonic acid metabolites in healthy volunteers
707
2.P.343 Fluvastatin reduces platelet activity in vitro
708
2.P.344 Platelet function in hypercholesterolemia - importance of combine hyperlipidemia
709
2.P.345 The role of the C-terminal of tissue factor pathway inhibitor (TFPI) in inhibition of the extrinsic pathway of coagulation
710
2.P.347 Plasminogen activator inhibitor-1 in human fat: Effect of tumor necrosis factor-α and pentoxifylline
711
2.P.348 Alpha fibronogen genotype is associated with the porosity and density of the fibrin gel matrix in MI patients
712
2.P.349 Protein S deficiency as an additional risk factor for juvenile TIA
713
2.P.35 Lipid-lowering effect of atorvastatin in homozygous familial hypercholesterolemia patients with portocaval anastomosis
714
2.P.350 A therapeutic dosage (3 g/day) of borage oil supplementation has no effect on platelet aggregation in healthy volunteers
715
2.P.351 Lysophosphophatidycholine inhibits tissue factor expression
716
2.P.352 Low or medium dose acetylsalicylic acid increases fibrin gel porosity is healthy adults
717
2.P.353 PAI-1 genotype, PAI-1 level and risk of thrombotic complications after renal transplantation
718
2.P.354 The factor V leiden (R506Q) mutation and risk of thrombosis in renal transplant recipients
719
2.P.355 Protease-activated receptor genes are clustered on 5q13
720
2.P.356 Fibrinogen synthesis in chronic smokers is significantly reduced after short-term cessation from smoking
721
2.P.357 The effects of physiological meals containing structured triglycerides with different fatty acid compositions on postprandial haemostasis
722
2.P.358 Prognostic value of haemorheological, haemostatic and fibrinolytic changes in progressing of cerebrovascular disorders
723
2.P.359 Is plasma fibrinogen before heart transplantation an independent predictor of graft vessel disease?
724
2.P.36 The efficacy of once-nightly niacin (Niaspan) on lipoproteins in dyslipidemic patients
725
2.P.360 Lipo-Merz reduces levels of fibrinogen and factor VII in patients with arterial hypertension
726
2.P.361 Nicotinic acid lowers P-fibrinogen and stimulates fibrinolysis!
727
2.P.363 Effects of long term administration of eicosapentaenoic acid on serum levels of tissue plasminogen activator and its inhibitor
728
2.P.364 Myocardial fibrin deposits in first month after transplantation predict subsequent coronary artery disease in cardiac allograft recipients
729
2.P.365 Coronary heart disease is associated with alterations in the daytime fluctuation pattern of plasminogen activator inhibitor 1 levels both in non-insulin-dependent diabetes patients and in nondiabetic subjects
730
2.P.366 High prevalence of homozigosity for the 677C → T mutation of the 5;10-methylenetetrahydrofolate reductase gene and hyperhomocysteinemia in patients with early-onset thrombotic events
731
2.P.367 Protection of exercise induced pro-thrombosis by aspirin
732
2.P.368 Factor VII: A responds to fatty meals, independently of fat composition
733
2.P.369 Procoagulant factors and cholesterol
734
2.P.37 Fenofibrate decreases the fibrinogen contents depending on its basal plasma levels in patients with hyperlipidemia
735
2.P.370 Effect of simvastatin treatment on thrombin generation in marked hypercholesterolemia
736
2.P.371 In vivo thromboxane/prostacyclin balance unfavourable affected in humans after diets rich in stearic acid or trans fatty acids
737
2.P.372 Contribution of fibrinogen to elevated plasma viscosity in patients with familial hypertriglyceridemia
738
2.P.373 Different effects of wine and red wine polyphenols on PAI-1 in healthy men
739
2.P.374 Changes of blood rheology by lipid oxidation as risk factor for thrombosis
740
2.P.375 Tissue factor pathway inhibitor inhibits aortic smooth muscle cell migration induced by tissue factor/factor VIIa complex
741
2.P.376 Effect of hirulog-1 on fibrinolysis and platelet deposition
742
2.P.377 Collagen-targeted antibodies could prevent acute thrombosis following PTCA
743
2.P.378 Correlation of haemostatic variables and structural changes of major arteries of the head in ischemic stroke patients
744
2.P.379 D-Dimers and fibrinogen in patients with left ventricle-dysfunction after myocardial infarction and in generalized atheriosclerosis
745
2.P.38 Long-term effects of low dose Omacor® in patients with severe hypertriglyceridemia
746
2.P.380 GPIIbIIIa inhibitors reduce procoagulant activity of platelet-derived microparticles (MP) by inhibiting their formation but not binding to fibrin(ogen)
747
2.P.381 A common mutation (G−455 → A) in the β-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease. A study of 9,127 individuals based on the Copenhagen City Heart Study
748
2.P.382 Fibrinolytic indicators inplasma and the generation of vascular plasmin in human arteriosclerosis
749
2.P.383 Aspirin-like effects of wine polyphenols on platelet aggregation in healthy men
750
2.P.39 Effect of bezafibrate on atherogenic lipoproteins in Japanese familial combined hyperlipidemic patients with or without impaired glucose tolerance
751
2.P.4 Expression of the human phospholipid transfer protein by the yeast Pichia pastoris
752
2.P.40 Discovery of the squalene synthetase inhibitor CP-340,868
753
2.P.41 Two year treatment experience with high dose atorvastatin
754
2.P.42 An overview of the clinical efficacy profile of atorvastatin
755
2.P.43 Mechanisms of pravastatin effects on plasma lipoprotein subfractions, estimated by activities of LCAT, CETP and lymphocyte LDL-receptor
756
2.P.44 Can fluvastatin be effectively used in the treatment of combined hyperlipidemia?
757
2.P.45 Targeting high risk patients with hypercholesterolemia: The efficacy and safety of simvastatin 80 mg/d
758
2.P.46 Associations of changes in blood lipids and hemostatic factors during fenofibrate treatment in dyslipidemic patients with polymetabolic syndrome (PMS)
759
2.P.47 Is there an effect of defined molecular defect on therapeutic response to HMG Co A reductase inhibitors in patients with familial hypercholesterolaemia?
760
2.P.48 Lipid-regulating effects of new classes of squalene epoxidase inhibitors
761
2.P.49 KY-455, a new bioavailable ACAT inhibitor with anti-peroxidative activity
762
2.P.5 In vitro factors affecting the concentration of gamma-LpE (γ-LpE) in human plasma
763
2.P.50 Niacin, by inhibiting both fatty acid synthesis and triacylglycerol formation, augments apo B degradation in Hep G2 cells
764
2.P.51 Escape phenomenon during the long-term administration of pravastatin for phyperlipideia associated with diabetes
765
2.P.52 Comparison of type II hyperlipoproteinemic patients with apoprotein E2, E3, and E4 phenotypes with respect to the response of plasma levels of lipids and apoproteins to simvastatin
766
2.P.53 Effects of long-term (for 5 years) treatment using pravastatin sodium on hyperlipidemia in diabetics
767
2.P.54 A two-year intensive lipid lowering in patients with familial hypercholesterolemia
768
2.P.55 ACAT inhibition by CI-1011 lowers plasma triglycerides in rats by enhancing the clearance of VLDL
769
2.P.56 Ciprofibrate in the treatment of hypertensive postmenopausal women with hyperlipidaemia IIa
770
2.P.57 Effect of atorvastatin on key enzymes regulating lipid metabolism in the cholesterol/coconut oil fed rabbit
771
2.P.58 Effects of atorvastatin on endothelium-dependent relaxations and contractions in dyslipidemic rabbits
772
2.P.59 Efficacy and safety of cerivastatin, a novel potent HMG-CoA reductase inhibitor, in primary hypercholesterolaemia: A comparative study
773
2.P.6 Mutations of the branchpoint concensus sequence of intron 4 of lecithin: Cholesterol acyltransferase (LCAT) gene
774
2.P.62 Effect of eicosapentaenoic acid in combination with HMG-CoA reductase inhibitor on lipid metabolism
775
2.P.64 Biopharmaceutical profile of cerivastatin, a novel HMG-CoA reductase inhibitor
776
2.P.65 Stimulation of bile acid production by the ACAT inhibitor HL-004
777
2.P.66 Dose-related reduction of LDL-cholesterol in patients with primary hypercholesterolemia by atorvastatin
778
2.P.67 Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin
779
2.P.68 Difference in effect of simvastatin on DNA synthesis among cultured human cell types
780
2.P.69 Effect of itraconazole on serum concentrations of simvastatin and pravastatin
781
2.P.7 Age-related decline in plasma CETP and CETP mRNA expression in human adipose tissue
782
2.P.70 Effect of policosanol on smooth muscle cell proliferation in the cuffed carotid artery of the rabbit
783
2.P.71 NK-104, a potent HMGCoA-reductase inhibitor, increases intracellular degradation of apo B-100 and decreases its secretion in HepG2 cells
784
2.P.71 NK-104, a potent HMGCoA-reductase inhibitor, increases intracellular degradation of apo B-100 and decreases its secretion in HepG2 cells
785
2.P.72 Atorvastatin inhibition of NF-βB activation in vascular smooth muscle cells is mediated by protein isoprenylation blockade
786
2.P.74 Efficacy and safety of ciprofibrate and lovastatin in treatment of hyperlipidemia
787
2.P.75 Long-term effects of pravastatin in cyclosporine treated heart recipients
788
2.P.76 Fluvastatin or bezafibrate alone versus their combination
789
2.P.77 Lipid-lowering therapy in secondary prevention by Swiss primary care physicians: How far are we from the target values?
790
2.P.78 Factors associated with non-use of lipid-lowering drugs in secondary prevention of coronary heart diseases. EUROASPIRE study
791
2.P.79 Cholesteryl ester storage disease: Molecular defects and treatment with the HMGCoA-reductase inhibitor lovastatin
792
2.P.8 Expression of CETP mRNA by stromal vascular cells of human adipose tissue
793
2.P.80 Effects of cerivastatin 0.3 mg daily compared to 0.15 mg in patients with hypercholesterolemia
794
2.P.81 Limitation of heart growth in neonatal piglets by simvastatin but not pravastatin
795
2.P.82 Effect of atorvastatin vs. simvastatin in patients undergoing regular LDL-apheresis (ASLA I)
796
2.P.83 Effect of simvastatin on cholesterol homeostasis in hamsters fed a sucrose-rich lithogenic diet
797
2.P.84 Effect of simvastatin on hepatic cholesterol metabolism and biliary lipids in Australian gallstone patients
798
2.P.85 Cholesterol-independent effects of pravastatin on atherosclerotic plaque stability in primates
799
2.P.86 Effects of silymarin and silybin on lipoprotein cholesterol levels and oxidizability of low density lipoprotein in rats
800
2.P.87 Reduction of oxysterol levels up-regulates HMG-CoA reductase activity in rat liver
801
2.P.87 Reduction of oxysterol levels up-regulates HMG-CoA reductase activity in rat liver
802
2.P.88 Fluvastatin in higher dosage reduces also triglyceride rich lipoproteins
803
2.P.89 Effect of four week long treatment with fenofibrate on the level of 7-ketocholesterol in hyperlipidemic patients
804
2.P.9 Reduced plasma HDL-cholesterol levels in visceral obesity: Contribution of the CETP gene TaqIB polymorphism
805
2.P.91 Effect of Lifibrol on the metabolism of LDL-apo B and apo A-I in moderate hypercholesterolemia
806
2.P.92 Effect of MCC-134, a novel antihypertensive agent, on lipid metabolism and vascular smooth muscle cell proliferation in rats
807
2.P.93 Influence of lifibrol therapy on apoB metabolism in mixed hyperlipidemia and hypercholesterolemic patients
808
2.P.93 Influence of lifibrol therapy on apoB metabolism in mixed hyperlipidemia and hypercholesterolemic patients
809
2.P.94 Reduction of plasma cholesterol levels and inhibition of smooth muscle cell (SMC) proliferation by cerivastatin sodium, a new HMG-CoA reductase inhibitor
810
2.P.95 Effect of simvastatin and theofibrate on lipid and lipid peroxidation in type II hypercholesterolemic patients
811
2.P.96 The use of Acipimox as second line drug in severe hypertriglyceridemia and combined hyperlipidemia patients
812
2.P.97 Relation of lipoprotein Lp(a) concentration and apolipoprotein apo(a) phenotypes to the presence and severity of carotid atherosclerosis
813
2.P.98 Predictive value of lipoprotein(a) for peripheral vascular disease in a community-based cohort
814
2.P.99 A novel kringle-4 number-based recombinant apo(a) standard for human Lp(a) phenotyping
815
2.S.1 Atherothrombosis in the heart and brain: New insights into the role of plasma lipoproteins
816
2.W10.1 Regulation of apoptosis in vascular smooth muscle cells
817
2.W11.4 Comparison of risk factor levels in Framingham Cohort and Offspring participants
818
2.W11.5 Cardiovascular risk factors in coronary patients across Europe
819
2.W12.4 Percutaneous arterial gene therapy for the prevention of restenosis
820
2.W12.5 Adventitial gene transfer to rabbit carotid arteries
821
2.W13.1 Molecular genetics as tools to redefine the clinics of lipoprotein disorders: The example of lipoprotein lipase deficiency
822
2.W13.5 FDB-100: Diagnosis, laboratory and clinical findings, possibilities of treatment. Experience from homozygous and heterozygous patients
823
2.W14.2 Chronic plaque growth or acute rupture? The yin and yang of vascular connective tissue remodelling
824
2.W15.1 Different approaches to the detection and quantification of triglyceride-rich lipoprotein remnants
825
2.W15.4 Effect of triglyceride-rich lipoproteins on cholesterol transport and atherosclerosis
826
2.W15.5 Familial combined hyperlipidemia (FCH): Causes and consequences
827
2.W16.1 Hormonal replacement therapy of menopause and atherosclerosis
828
2.W16.3 Hormone replacement therapy, thrombosis, and haemostasis
829
2.W16.4 The impact of HRT on selected vascular and metabolic risk factors for atherosclerosis
830
2.W16.5 Hormonal agents used in lowering lipoprotein(a)
831
2.W17.1 Structural and functional consequences of non-enzymatic glycation of apolipoprotein A-I and its impact on the reverse cholesterol transport
832
2.W17.2 Caveolin-dependent free cholesterol efflux — major regulatory pathway in peripheral cells
833
2.W17.4 HDL and cellular cholesterol efflux
834
2.W17.5 Genetic determinants of HDL and their relationships to atherosclerosis
835
2.W18.1 Cellular metabolism of triglyceride-rich lipoproteins
836
2.W18.2 The effect of leukaemia inhibitory factor on experimental atherosclerosis
837
2.W18.3 Lipoprotein association with cells and matrix: Modulation by lipase and proteoglycans
838
2.W18.4 Arterial-wall sphingomyelinase and atherogenesis
839
2.W18.5 Lipid oxidation products as regulators of macrophage function in atherosclerosis
840
2/3 A-size rechargeable battery employing LiCoO2 thin-film cathode
841
2: External Validation of the Mortality in Emergency Department Sepsis (MEDS) Score: A Multi-Center Prospective Cohort Study
842
2: Hydrothermal ore deposits related to post-orogenic extensional magmatism and core complex formation: The Rhodope Massif of Bulgaria and Greece
843
2: Radiographs Versus CT for the Initial Diagnosis of Blunt Cervical Spine Injury: A Prospective Comparison
844
2:1 Atrioventricular Block During Atrioventricular Node Reentrant Tachycardi
845
2:1 Atrioventricular block: Order from chaos
846
2:1 Ba/Ti(IV) Heterobimetallic complex based on two calix[6]arenes
847
2-[(1E)-({[(Benzyl­sulfan­yl)methane­thio­yl]amino}­imino)­meth­yl]-6-meth­­oxy­phenol: crystal structure and Hirshfeld surface analysis
848
2-[(1E)-[(Z)-2-({[(1Z)-[(E)-2-[(2-Hy­dr­oxy­phen­yl)methyl­­idene]hydrazin-1-yl­­idene]({[(4-methyl­phen­yl)meth­yl]sulfan­yl})meth­yl]disulfan­yl}({[(4-methyl­phen­yl)meth­yl]sulfan­yl})methyl­­idene)hydrazin-1-yl­­idene]meth­yl]phenol: crystal structure, Hirshfeld surface analysis and computational study
849
2-[(2,4,6-Tri­methyl­benzene)­sulfon­yl]phthalazin-1(2H)-one: crystal structure, Hirshfeld surface analysis and computational study
850
2-[(4-Chloro­phen­yl)selan­yl]-3,4-di­hydro-2H-benzo[h]chromene-5,6-dione: crystal structure and Hirshfeld analysis
851
2-[(8-Dimethylaminonaphthalen-1-yl)dimethylsilyl]-N,N,4,4-tetramethyl-1,2,3,3a,4,5-hexahydro-4-sila-5,9b-ethenobenz[e]inde-9-amine. An unexpected by-product from the reaction of 1-lithio-8-dimethylaminonaphthalene with chlorodimethylvinylsilane
852
2-[(Alkylsulfonyl)oxy]-6-substituted-1H-isoindole-1,3(2H)-dione mechanism-based inhibitors of human leukocyte elastase
853
2-[(Diphenylphosphino)methyl]-6-methylpyridine (PN) coordination chemistry at triosmium clusters: Regiospecific ligand activation and DFT evaluation of the isomeric Os3(CO)10(PN) clusters
854
2-[(R-phenyl)amine]-1,4-naphthalendiones as photosystem I electron acceptors. Structure-activity relationship of m- and p-PAN compounds with QSAR analysis
855
2-[(substituted)phenyl]-5-[1-(2-phenylazacycloheptyl)methyl]-1H-pyrroles with high affinity and selectivity for the dopamine D3 receptor
856
2-[1-(2,6-Dibenzhydryl-4-chlorophenylimino)ethyl]-6-[1-(arylimino)ethyl]pyridyliron(II) dichlorides: Synthesis, characterization and ethylene polymerization behavior
857
2-[1-(2,6-dibenzhydryl-4-chlorophenylimino)ethyl]-6-[1-aryliminoethyl]pyridyl cobalt dichlorides: Synthesis, characterization and ethylene polymerization behavior
858
2-[1-(2,6-Dibenzhydryl-4-methylphenylimino)ethyl]-6-[1-(arylimino)ethyl]pyridylnickel(II) halides: Synthesis, characterization and ethylene oligomerization behavior
859
2-[18F]-Fluoro-2-deoxy-d-glucose positron emission tomography as guidance for primary treatment in patients with advanced-stage resectable squamous cell carcinoma of the larynx and hypopharynx
860
2-[18f]-Fluoro–2-deoxy-d-glucose positron emission tomography in the evaluation of breast lesions and axillary involvement: a comparison with mammography and histopathological diagnosis
861
2-[18F]-fluoroisonicotinic acid hydrazide: biological evaluation in an acute infection model
862
2-[2-(4-Methoxyphenyltelluro)ethyl]thiophene (L1) bis[2-(2-thienyl)ethyl] telluride (L2) and their metal complexes; crystal structure of trans-dichlorobis{2-(2-(4-methoxyphenyltelluro)ethyl)thiophene-Te}palladium(II) and {bis[2-(2-thienyl)ethyl] telluride
863
2-[4-(Dimethylamino)phenyl]-3-hydroxy-4H-chromene-4-one: A H-bond-sensitive fluorescent probe for investigating binary mixtures of organic solvents Original Research Article
864
2-[4-(o-methoxyphenyl)piperazin-1-ylmethyl]-1,3-dioxoperhydroimidazo[1,5-a]pyridine as a new selective 5-HT1A receptor ligand
865
2-[Carbamo­thio­yl(2-hy­dr­oxy­eth­yl)amino]­ethyl benzoate: crystal structure, Hirshfeld surface analysis and computational study
866
2-[N1-2-Pyrimidyl-aminobenzenesulfonamido] ethyl 4-bis(2-chloroethyl) aminophenyl butyrate: A potent antitumor agent
867
2-{(1E)-[(E)-2-(2,6-Di­chloro­benzyl­­idene)hydrazin-1-yl­­idene]meth­yl}phenol: crystal structure, Hirshfeld surface analysis and computational study
868
2-{[1-(3,4-Dihydroxyphenyl)methylidene]amino}benzoic acid immobilized Amberlite XAD-16 as metal extractant
869
2-{2-[3-(Pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl}pyridine: a highly potent, orally active, metabotropic glutamate subtype 5 (mGlu5) receptor antagonist
870
2′,2′-Ligation demonstrates the thermal dependence of DNA-directed positional control
871
2′,3′,4′,5′-Tetraacetyl-N(3)-carboxymethylriboflavin derivatives: synthesis and fluorescence studies
872
2′,3′-Didehydro-2′,3′-dideoxynucleosides are degraded to furfuryl alcohol under acidic conditions
873
2′,5′-Oligoadenylate-peptide nucleic acids (2–5A-PNAs) activate RNase L Original Research Article
874
2′-Amino-2′-deoxy-N6-(1-naphthylmethyl)adenosine as Novel Scaffold for a Polymer-Assisted Amidation Protocol
875
2′-Behenoyl-paclitaxel conjugate containing lipid nanoparticles for the treatment of metastatic breast cancer
876
2′-Carboxybenzyl glycosides: glycosyl donors for C-glycosylation and conversion into other glycosyl donors
877
2′-C-Methyluridine phosphoramidite: a new building block for the preparation of RNA analogues carrying the 2′-hydroxyl group
878
2′-Deoxy-2′(S)-ethinyl oligonucleotides: A modification which selectively stabilizes oligoadenylate pairing to DNA complements
879
2′-deoxy-8-(propyn-1-yl)adenosine-containing oligonucleotides: effects on stability of duplex and quadruplex structures
880
2′-Deoxyadenylyl-(3′→5′)-isodideoxyadenosine, a unique dinucleotide: Synthesis, enzymology, and conformational studies
881
2′-deoxycytidine in free nucleosides and double-stranded dna as the major target of lipid peroxidation products
882
2′-deoxyguanosine oxidation is associated with decrease in the DNA-binding activity of the transcription factor Sp1 in liver and kidney from diabetic and insulin-resistant rats
883
2′-Deoxy-N4-[2-(4-nitrophenyl)ethoxycarbonyl]-5-azacytidine: A novel inhibitor of DNA methyltransferase that requires activation by human carboxylesterase 1
884
2′-Fluoro Substituents Can Mimic Native 2′-Hydroxyls within Structured RNA
885
2′-Fluoro-3-deazaaristeromycin
886
2′-Hydroxyflavylium: introducing flavanones into the flavylium network of chemical reactions
887
2′-Lipid-modified oligonucleotides via a ‘Staudinger–Vilarrasa’ reaction
888
2′-Methyl and 1′-xylosyl derivatives of 2′-hydroxyflexixanthin are major carotenoids of Hymenobacter species
889
2′-Methyl taxanes: synthesis and NMR configurational assignment
890
2′-Nitroflavone induces cell cycle arrest and apoptosis in HeLa human cervical carcinoma cells
891
2′-O,4′-C-ethylene-bridged nucleic acids (ENA): highly nuclease-resistant and thermodynamically stable oligonucleotides for antisense drug
892
2′-O,4′-C-methylene bridged nucleic acid (2′,4′-BNA): synthesis and triplex-forming properties Original Research Article
893
2′-O-{[2,2-dimethyl-2-(2-nitrophenyl) acetyl] oxy} methyl protecting group for RNA synthesis
894
2′-O-Carbamate-containing oligonucleotides: synthesis and properties
895
2″-O-Glucosylvitexin, a chemotaxonomic marker for the genus Cryptocoryne (Araceae)
896
2″-Substituted 5-phenylterbenzimidazoles as topoisomerase I poisons Original Research Article
897
2+1 dimensional charged black hole with (anti-)self dual Maxwell fields
898
2+1 resonance-enhanced multiphoton ionisation spectroscopy of the high ν2 levels of the B̃1E″ Rydberg state of NH3(ND3)
899
2+1+1 two-color REMPI study of the E1Π(ν=1)←D1Δ(ν=10)←X1Σ+(ν=0) transition in CO: influence of the accidental predissociation in the CO E1Π(ν=1) state at j=9 and 10
900
2+2 may (or may not) yield 4
901
2× oversampling 2.5 Gbps clock and data recovery with phase picking method
902
2×2 superlattices
903
2×2 systems of conservation laws with L∞ data
904
2×CO2 Eastern Asia regional responses in the RSM/CCM3 modeling system
905
2·5 year remission of AIDS-associated progressive multifocal leukoencephalopathy with combined antiretroviral therapy
906
20 000 brains removed and retained without relativesʹ consent
907
20 Isometric strength of the small tears of the rotator cuff
908
20 K Energy storage unit Original Research Article
909
20 million contract
910
20 Mini vs. open repair of isolated supraspinatus tendon tears
911
20 most-cited countries in clinical medicine ranked by population size
912
20 Myr of eccentricity paced lacustrine cycles in the Cenozoic Ebro Basin
913
20 Pravastatin protects against development of chronic rejection in rat cardiac allografts and upregulates immunosuppressive TGF-B2
914
20 S proteasomes are imported as precursor complexes into the nucleus of yeast
915
20 Segment based interpolation revisited
916
20 thickened, fragile nails
917
20 years of active deformation on volcano caldera: Joint analysis of InSAR and AInSAR techniques
918
20 Years of Cardiac Resynchronization Therapy
919
20 years of experience in idiopathic central diabetes insipidus
920
20 years of mass balances on the Piloto glacier, Las Cuevas river basin, Mendoza, Argentina
921
20 years of patch testing with (meth)acrylates
922
20 years of scripted space
923
20% loss of unimproved farmland in 22 years in the Engadin, Swiss Alps
924
20% of sufferers could outgrow peanut allergy
925
20 My of nitrogen fixation during deposition of mid-Cretaceous black shales on the Demerara Rise, equatorial Atlantic Ocean
926
20(S)-Protopanaxatriol, one of ginsenoside metabolites, inhibits inducible nitric oxide synthase and cyclooxygenase-2 expressions through inactivation of nuclear factor-κB in RAW 264.7 macrophages stimulated with lipopolysaccharide
927
20. Clinical and radiological predictors of complete excision in breast conserving treatment
928
20. Declining motor unit number estimates in a murine model of kennedy’s disease
929
20. Evaluation of oestrogen and progesterone receptors in breast cancer by comparing computer-assisted image analysis of immunocytochemical assay with enzyme immunoassay
930
20. Heart failure transition clinics: Can they reduce heart failure readmissions?
931
20. Heart failure… at home – sweet home
932
20. Multimodal intraoperative monitoring during spine surgery
933
20. rCBF measured by NIRS varies with the deep brain stimulation for STN
934
20/20 Foresight Crafting Strategy in an Uncertain World,: by Hugh Courtney, Harvard Business School Press, Boston, Massachusetts, 2001. ISBN 1-57851-266-2.
935
20/sup st/ century engineer-entrepreneur
936
20: A Comparison of Endotracheal Intubation Success Rates Between Providers of a Metropolitan Air Medical Transport Service
937
20: CT Coronary Angiography During Initial Visit Decreases Rate of Return Visits Relative To Standard Care
938
200 junior doctors sacked in Zambia
939
200 MeV Ag+15 ion irradiation created columnar defects and enhanced critical current density of La-2125 type superconducting thin films
940
200 MeV Ag15+ ion induced surface modification and transport behaviour in manganite based thin film devices
941
200 Years of British Hydrogeology, Mather J.D. (Ed.). Geological Society, London (2004), 394
942
200 years of practical electroanalytical chemistry: past, present and future directions illustrated by reference to the on-line, on-stream and off-line determination of trace metals in zinc plant electrolyte by voltammetric and potentiometric techniques O
943
200 000 yr diatom records from Atlantic upwelling sites reveal maximum productivity during LGM and a shift in phytoplankton community structure at 185 000 yr
944
2000 ACC/AHA guidelines for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction: A practical summary for emergency physicians
945
2000 ACM Conference on Intelligent User Interfaces
946
2000 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System
947
2000 John Cedric Griffiths teaching award of the international association for mathematical geology
948
2000 Shanghai Magnolia Award
949
2000 to 2015: How Far Have We Progressed in Achieving the Health Related Millennium Development Goals?
950
2000 years of sustainable use of watersheds and coral reefs in Pacific Islands: A review for Palau
951
2000 ans de colmatage du port antique de Fréjus (Forum Julii), France : une double métamorphose littorale
952
2000 years of frequent turbidite activity in the Capbreton Canyon (Bay of Biscay)
953
200000 yr diatom records from Atlantic upwelling sites reveal maximum productivity during LGM and a shift in phytoplankton community structure at 185000 yr
954
2000–2003 real estate bubble in the UK but not in the USA
955
2000-Ma sulphide concretions from the `Productiveʹ Formation of the Pechenga Greenstone Belt, NW Russia: genetic history based on morphological and isotopic evidence
956
2000-year environmental history of a karstic lake in the Mediterranean Pre-Pyrenees: the Estanya lakes (Spain)
957
2001 – A Controversy
958
2001 Ambassador Award: Mid-Atlantic Chapter Society of Toxicology
959
2001 assessment of nutritional influences on risk for cataract
960
2001 Bhuj, India, Earthquake Engineering Seismoscope Recordings and Eastern North America Ground-Motion Attenuation Relations
961
2001 Consensus guidelines for the management of women with cervical intraepithelial neoplasia
962
2001 consensus guidelines for the management of women with cervical intraepithelial neoplasia
963
2001 Cumulative article and author index volume 44, number 6
964
2001 Felix Chayes prize for excellence in research in mathematical petrology of the international association for mathematical geology
965
2001 flank eruption of the alkali- and volatile-rich primitive basalt responsible for Mount Etnaʹs evolution in the last three decades
966
2001 ISPMB discounts for Plant Molecular Biology
967
2001 Kumho Science International Award in Plant Molecular Biology and Biotechnology Award Presentation ceremony
968
2001 LCATS research award
969
2001 meeting Southern Thoracic Surgical Association
970
2001 transcatheter cardiovascular therapeutics
971
2001 transcatheter cardiovascular therapeutics
972
2001 transcatheter cardiovascular therapeutics
973
2001 UTS Society for Utopian studies conf
974
2001: A Veterinary Odyssey – Here and Now
975
2001—the year for health-research ethics to take centre stage?
976
2002 AA29: Earthʹs recurrent quasi-satellite?
977
2002 annual report of the American association of poison control centers toxic exposure surveillance system
978
2002 Elections in Pakistan: A Reappraisal
979
2002 Henry H. Storch Award
980
2002 Kuiper prize lecture: Dust Astronomy
981
2002 Kumho Science International Award in Plant Molecular Biology and Biotechnology
982
2002 Leonid storm fluxes and related orbital elements
983
2002 Reviewers List
984
2002 Rumelhart prizewinner
985
2002 St. Christopher lecture
986
2002 state of the science: Celebration of sharing
987
2002 summer fires in Lithuania: Impact on the Vilnius city air quality and the inhabitants health
988
2002 update to the ACC/AHA guidelines for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction: Implications for emergency department practice
989
2002 Winter Conference on Plasma Spectrochemistry: Scottsdale Arizona 6–12 January 2002
990
2002: the year of the ‘diversity – ecosystem function’ debate
991
2002-2008 Yılları Arasında Erzurum Bölgesinde Birinci ve İkinci Basamak Sağlık Hizmetlerinin Değerlendirilmesi
992
2003 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System ,
993
2003 Author index
994
2003 European Winter Conference: 2003 European Conference on Plasma Spectrochemistry January 12–17, 2003
995
2003 International Ash Utilization Symposium
996
2003 Kumbo Science International Award in Plant Molecular Biology and Biotechnology: Awardee is Xing-Wang Deng
997
2003 Kumho Science International Award in Plant Molecular Biology and Biotechnology
998
2003 LCATS Research Award: Robert P. Holley
999
2003 Meeting Southern Thoracic Surgical Association
1000
2003 Performance Evaluation reviewers